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ABSTRACT
ALTERNATIVE METHODS OF THE TREATMENT OF CHEMO-RESISTANT 
CANCERS
MAY 2016
KAITLYN E. WONG B.S., STATE UNIVERSITY OF NEW YORK AT STONY 
BROOK
M.P.H., TUFTS UNIVERSITY
M.D., TUFTS UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sallie S. Schneider
 
 Great strides have been made in cancer therapy  in the past century, yet it remains 
one of the leading causes of death in the United States today. This work aimed to shed 
light on novel methods to treat a variety of aggressive and often chemo-resistant cancers 
both in vitro and in vivo. 
 The first aim of this work was to evaluate the therapeutic efficacy of poly
(methacryloyloxyethyl phosphorylcholine) (polyMPC) prodrugs compared to standard 
chemotherapeutic agents. Conjugation of polyMPC to drugs such as doxorubicin (Dox) 
can result  in its improved solubility, prolonged half-life and therapeutic efficacy. 
PolyMPC and polyMPC-Dox (at a dose less than 10mg/kg) was observed to be safe for 
systemic administration in a murine model. Additionally, treatment with polyMPC-Dox 
resulted in improved survival and reduced off target toxicities in mice with orthotopic 
human ovarian xenografts. Further, mesenchymal stem cells (MSCs) were observed to 
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successfully  uptake polyMPC and home to breast cancer xenografts in vivo and thus can 
potential serve as a vehicle to improve drug delivery. 
 Additional aims of this work focused on evaluating the root extract of Rhodiola 
crenulata (RC) plants for the treatment of aggressive cancers derived from the neural 
crest, including neuroblastoma and melanoma.  RC was observed to reduce growth and 
migration of melanoma in vitro. Further, RC resulted in reduction of aggressive tumor 
characteristics upon topical therapy  as well as the reduced establishment of metastatic 
foci upon enteral administration in mice with melanoma. While no difference in 
outcomes was observed upon RC treatment in a disseminated neuroblastoma model in 
vivo, RC did result  in striking cytotoxic effects upon treatment of neuroblastoma cells in 
vitro. These cytotoxic effects of RC likely resulted from derangements altering the cell’s 
ability to undergo optimal cellular metabolism.
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CHAPTER 1
INTRODUCTION
1.1 Significance
 Cancer remains a critical public health concern as it continues to be one of the 
leading causes of death, not just in the United States, but throughout the world. The 
American Cancer Society projected that more than 1.6 million new cancer diagnoses, 
excluding basal and squamous skin cancers and non-invasive in situ cancers, were 
diagnosed in 2015 in the United States [1]. Further, more than half a million deaths in the 
Unites States were a result of cancer in 2015 [1]. Only  heart disease and accidental 
trauma results in more deaths than cancer, in adults and children respectively, in the 
United States annually. There is a greater than 38% lifetime risk (38% female, 43% male) 
of developing cancer in the average American [1]. While significant improvements in 
detection and treatments for cancer over the last few decades have resulted in the 
downward trend of the incidence of cancer and death resulting from this disease [2], still 
it contributes a significant burden to the health care of our society. 
 Evaluation of novel methods to not only treat cancer but to improve currently 
available therapeutic options can enhance treatment efficacy and result in improved 
patient outcomes and survival. The research presented in this thesis seeks to evaluate 
polyMPC polymer prodrugs and Rhodiola crenulata (RC) plant extracts for the treatment 
of a variety of chemo-resistant cancers both in vivo and in vitro. 
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1.2. Current Cancer Therapeutic Strategies
 The treatment of cancer, depending on the stage of the disease at presentation, 
often requires a multidisciplinary approach to therapy combining medicine, surgery  and/
or radiation. While surgery and radiation are more loco-regional based efforts of 
treatment, chemotherapeutic drugs, typically  provided systemically, are utilized in more 
invasive and disseminated stages of disease [3]. A variety of classes of chemotherapeutic 
agents are available, many of which non-specifically target rapidly growing and dividing 
cells, including cancer cells. These drugs are also associated with severe side effects 
related to dosing, biodistribution and the pharmacokinetics of these agents. While side 
effects can be as generalized as fatigue and gastrointestinal complaints, specific drugs can 
result in significant toxicities, resulting in devastating morbidities such as cardiac, renal 
or neurotoxicities [3]. The severity of these side effects can limit optimal dosing or even 
the utilization of these agents entirely despite their potential therapeutic benefit. 
 Investigation into novel agents and means to improve current  therapy is ongoing. 
Novel treatment classes, such as immunologic agents, have been developed. These agents 
enhance immune function, promoting both innate and adaptive immunologic anti-tumor 
defenses [4]. Additionally, genetic and proteomic profiling have also been evaluated to 
optimize therapy  for each patient based on their specific tumor characteristics. 
Investigation also continues to identify naturally  available treatment agents, such as 
bioactive fractions of plant based phytochemicals that may provide us with novel 
treatment or preventative agents. Finally, additional strategies to improve traditional 
chemotherapeutic agents have also been employed. A variety  of methods have been 
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utilized to improve tumor targeting and drug delivery through both active and passive 
mechanisms, thus improving the efficacy and tolerance of these agents. 
  
1.3 Polymer Based Therapeutic Agents
 The creation of prodrugs is one method to improve the effectiveness of available 
chemotherapeutic agents. Prodrugs are created through the modification of drugs by 
means of binding biologically inactive moieties to these agents to alter their biologic 
properties upon administration in vivo [5]. When administered systemically, the drug is 
often inert given it’s attachment to the bound chemical molecules. The prodrug can be 
modified by a variety  of means, including enzymatic and chemical modifications, in 
order to release the drug in its active form and at the optimal site of action, such as within 
a tumor. The goals of utilizing prodrugs are to increase drug uptake by tumors and reduce 
unintended uptake of these drugs by other organs [4-6]. Utilization of prodrugs can allow 
for improved drug tolerance through allowance of higher drug administration or through 
reduction of harmful side effects that could limit drug tolerance. 
 The chemical moieties employed to create prodrugs can also allow for improved 
pharmacokinetic and biodistributive profile as the utilized scaffolds can improve drug 
solubility and half life of the index agent. Further, improved tumor uptake of the drug in 
prodrug form can result secondary  to the enhanced permeability and retention (EPR) 
effect. This effect states that  larger and bulkier molecules bound to drugs are more likely 
to be taken up by  the leaky, disorganized vasculature of the tumor micro-environment 
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[6-9]. Uptake is further enhanced secondary to its prolonged circulation and decreased 
rate clearance provided by the conjugation of these drugs to polymers. 
 A variety of polymer nanocarriers, such as poly(ethylene glycol) (PEG) have been 
utilized for prodrug creation [4-6]. Several strategies are utilized to create prodrugs using 
polymers in which the drug can be conjugated to a preformed polymer, the drug can be 
bound to a monomer prior to polymerization or polymerization can be initiated following 
binding to the agent of interest [5]. Utilization of polymers as a means to create prodrugs 
provide several benefits as the synthesis of these facile molecules can be tailored in a 
variety of ways including shape, size and drug binding capacity allowing for alterations 
of drug availability  and release. Investigation into alternative polymers, such as poly (2-
methacryloyloxyethyl phosphorylcholine) (polyMPC), can result  in more efficacious and 
potentially better tolerated prodrugs [7-8]. 
1.4 Drug Delivery Vehicles
 In order to further enhance drug delivery, additional means to deliver treatment 
agents are necessary.  A variety of “carriers” have been evaluated as vehicles for drug 
delivery to improve targeting of drugs, such as liposomes or polymer micelle 
formulations [5,6,9]. These vehicles serve to not only shield drugs while in systemic 
circulation, thus preventing unintended exposure of these agents to certain tissues, but 
can also result in improved drug targeting specifically within the tumor bed. Several 
clinically  relevant drug formulations employ  these techniques. For example, doxil is a 
liposomal formulation of the anthracycline agent, doxorubicin (Dox) [10,11].  Through 
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utilization of a liposomal carrier, Dox uptake within the tumor is enhanced and it’s uptake 
in cardiac tissues is reduced, resulting in improved therapeutic efficacy  and less 
cardiotoxicity [11].
 Active targeting methods often employ ligand mediated targeting whereby 
ligands, such as antibodies, which are specific for cell surface molecules or receptors on 
tumors are bound to drugs resulting in very specific interactions required for drug 
delivery [6]. Alternative methods can also be utilized to further deliver drug directly to a 
tumor. Cellular vehicles hold promise as an alternative and potentially active means to 
promote drug delivery. A variety of cells including T-cells, macrophages and stem cells 
are known to have inherent migratory and tumoritropic abilities. The micro-environment 
of tumor stroma is similar to that of a healing wound and thus releases chemoattractant 
molecules which stimulate the migration of these cells to tumors. Mesenchymal stem 
cells (MSCs) are pluripotent progenitor cells with tumoritropic characteristics that are 
found throughout the body [12-16]. The therapeutic advantages of these cells have 
already been harnessed clinically, given their attraction to sites of injury, in order to treat 
tissue damaged from myocardial infarctions and strokes [17,18]. The tumoritropic 
properties displayed by MSCs can be taken advantage of therapeutically, as MSCs can be 
physically or genetically modified to deliver drugs or anti-cancer agents directly  to 
tumors. 
1.5 Phytochemicals and Cancer Therapy 
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 Natural products are agents derived from plants, animals and microbes that are 
potentially biologically and pharmaceutically active [19-21]. Almost a quarter of novel 
drugs developed for cancer treatment between 1981-2002 were composed of, derived 
from or were discovered in natural agents [20]. Many continue to remain under 
investigation, and are even undergoing evaluation in active clinical trials. 
Phytochemicals, or natural agents derived from plants, comprise a significant proportion 
of the products. Many phytochemicals are used for both the prevention or treatment of 
cancer [19-22]. There are four classes of plant based compounds that are currently 
utilized clinically for the treatment of cancer including vinca alkaloids, 
epipodophyllotoxins, taxanes, and camptothecins [21].  While phytochemicals are one of 
the key sources of agents utilized to treat cancer, still many of these plant based agents 
have yet to be evaluated critically for their ability  to treat cancer or provide insight into 
potential novel targets for cancer therapy. 
 Bioactive fractions from a variety of dietary plants or plant extracts have been 
utilized in traditional medicines for centuries and are known to treat or prevent the 
development of cancer. These agents can be derived from a vast  array  of plants, including 
licorice, ginger, green tea, as well as many  others [21]. These plant based products result 
in the prevention or treatment of cancer through a variety  of mechanisms. Several of the 
means to which these phytochemicals result in anti-tumorigenic effects on a wide array of 
cancers (either in vitro or in vivo) include anti-inflammatory  and pro-apoptotic properties, 
prevention of cellular epithelial to mesenchymal transitions, as well as prevention of 
metastatic spread and establishment [20,22]. 
6
 Rhodiola plants have been utilized medicinally for centuries in Eurasian cultures. 
The genus Rhodiola is composed of nearly 90 different species of plants which grow 
throughout Eastern Europe and Asia [19,23].  Rhodiola plants grow throughout regions of 
high altitude, cold climates and barren soil. Given this, these plants have evolved to 
produce a numerous adaptogenic compounds which allow the plant to thrive in such 
harsh environments. Many of the fractions of Rhodiola plants that display medicinal 
properties, such as salidroside, tyrosol, caffeic acid, rosin and rosavin, are classified as 
adaptogens as the are utilized to prevent the effects of cellular stressors [19,23-29]. Today 
Rhodiola extracts are available as a natural supplement used for the treatment of fatigue, 
depression, anemia, impotence, gastrointestinal ailments, infections, and nervous system 
disorders. These extracts are believed to convey  improved physical endurance and boost 
the immune system [19,24-29]. Extracts from Rhodiola crenulata (RC) are known to be 
bioactive and bioavailable and are under investigation as a therapy  in several types of 
cancers, including breast and bladder cancer [24-29]. RC extracts, and the compounds 
contained within it, have the potential to serve as a novel adjunct for the treatment of a 
variety of cancers.
7
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CHAPTER 2 
EVALUATION OF POLYMPC PRODRUGS IN A HUMAN OVARIAN TUMOR 
MODEL
This research was performed in close collaboration with Matthew Skinner and Dr. 
Carmen Mora. 
2.1 Introduction
 Ovarian cancer is the most lethal gynecological malignancy among women in the 
United States, and remains a leading cause of death with approximately 22,000 diagnoses 
and 14,000 deaths annually [1]. Early tumor detection is challenging, and patients often 
present with advanced, metastatic or disseminated disease at  diagnosis. Conventional 
treatment involves surgical de-bulking of solid tumor accompanied by chemotherapy. 
Doxorubicin (Dox), an anthracycline chemotherapeutic, is a prominent  treatment option 
for various hematologic cancers and solid tumors, including malignant ovarian neoplasms 
[2,3]. While Dox is a powerful anti-tumor agent, its efficacy  is limited by rapid clearance 
kinetics and non-specific accumulation in healthy  tissue. This poor specificity  leads to 
off-target toxicity  that causes myelosuppression, gastrointestinal irritation, and 
cardiotoxicity, thus limiting Dox dosing even when its use is effective for tumor 
reduction [2,4]. 
 To improve the therapeutic efficacy of Dox, specifically its pharmacokinetics, 
conjugation to polymers offers a convenient and attractive strategy. Polymer-drug 
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conjugation produces prodrugs of larger hydrodynamic size than the drug alone. This 
lengthens renal clearance half-life and prolongs in vivo circulation [5]. Coupling this 
improved pharmacokinetic profile with the enhanced permeability and retention (EPR) 
effect, whereby  polymer-drug conjugates penetrate into the leaky vasculature of tumors 
and become entrapped due to poor tumoral lymphatic drainage, drug uptake in solid 
tumors is enhanced and off-target organ accumulation is reduced [6-8]. For ease of 
delivery, hydrophilic polymers solvate otherwise water insoluble drugs at high loadings 
[9-11], and are potential replacements for other excipients, such as ethanol, which are 
problematic in some patient populations as they  can cause severe or even fatal 
anaphylactic reactions [12-13].
 Poly(2-methacryloyloxyethyl phosphorylcholine) (polyMPC) [14-15], is a 
hydrophilic polymer noted for its exceptional water solubility and biocompatibility 
[16-18]. Dox conjugation to polyMPC was achieved by formation of hydrazone bonds, 
which are acid-sensitive and thus cleavable in vivo.  Previous evaluation of polyMPC-
Dox prodrugs exhibited an in vivo circulation half-life of greater than two hours. Upon 
evaluation of polyMPC-Dox treatment on an aggressive mouse breast tumor model (4T1 
cell line), it’s administration reduced the mean tumor size and resulted in a two-fold 
increase in survival time over free Dox treated mice.  Dox in the prodrug animal group 
accumulated in tumors at twice the level of that observed in mice treated with free Dox. 
A corresponding reduction in off-target organ uptake was also observed.  
 To gauge the therapeutic breadth and clinical relevance of polyMPC-Dox, it’s 
efficacy was evaluated in human cancer through utilization of the SKOV-3 ovarian tumor 
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model in vivo. Experiments were performed with polyMPC and polyMPC-Dox to 
evaluate it’s in vivo biocompatibility and establish a maximum tolerated dose (MTD) of 
the prodrug. Mice with subcutaneously established SKOV-3 xenografts were treated with 
Dox, polyMPC-Dox or Doxil, an alternate liposomal Dox formulation [2], using a 
recurring dosing schedule resembling that employed for human patients [19]. Animals 
were monitored for symptoms of treatment associated toxicity, change in tumor size, and 
survival.  The overall accumulation of Dox and polyMPC-Dox in solid ovarian tumors 
was compared, as was the specificity for uptake in tumor tissue versus off-target organs. 
2.2 Materials and Methods
2.2.1 Cell Culture. 
 Human ovarian adenocarcinoma SKOV-3 cells were maintained in Roswell Park 
Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum, 
100U/mL penicillin, and 100µg/mL streptomycin at 37oC under 5% CO2  (Thermo fisher, 
Grand Island, NY).
2.2.2 Maximum Tolerated Dose of polyMPC and polyMPC-Dox. 
 The MTD of the polyMPC scaffold carrier and polyMPC-Dox prodrug were 
evaluated in seven week old non-obese diabetic severe combined immunodeficient  (NOD 
SCID) mice, as they are commonly  utilized for human tumor xenograft models [20, 21]. 
In order to evaluate the MTD of polyMPC, three mice per treatment group were 
administered two doses of polyMPC dissolved in Hank’s balanced salt solution (HBSS, 
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Thermo fisher, Grand Island, NY) at  doses of 50, 100, 200, 400 or 800 mg/kg via lateral 
tail vein injections administered on day 0 and day 17. The MTD of polyMPC-Dox was 
evaluated both via intraperitoneal and intravenous administration. Three mice per 
treatment group were administered a single dose of polyMPC-Dox in solutions of Dox 
equivalent doses of 10, 20, 30, 40 or 50 mg/kg administered via a single lateral tail vein 
injection or intraperitoneal injection.
 Weight, appearance and behavior of the mice were monitored daily for a total of 
35 days. Symptoms of toxicity  were defined as weight loss greater than 15% or evidence 
of distress in appearance or behavior. Animals exhibiting these criteria were euthanized 
prior to the end of the study. At the completion of the study, all remaining mice were 
euthanized and necropsy was performed to collect tissues for histologic evaluation
2.2.3 Biodistribution. 
 The uptake and accumulation of Dox within tumor tissue and off-target organs 
was evaluated in four week old NOD SCID mice following treatment with either free 
Dox or polyMPC-Dox. SKOV-3 ovarian human adenocarcinoma subcutaneous 
xenografts were established following injection of 1x107 cells in the right flanks of nine 
mice. Following tumor establishment and growth to a volume of 100-500mm3 (calculated 
by length X width2⁄2), three mice per treatment group  were administered HBSS, 
polyMPC-Dox (6 mg/kg Dox equivalent) or free Dox (6 mg/kg) via lateral tail vein 
injection. Three days following the injections, mice were euthanized and organs (liver, 
kidneys, spleen, heart, lungs) and tumor were resected, weighed, and then flash frozen in 
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liquid nitrogen. All tissues were stored at -80°C prior to analysis. Dox accumulation in 
the resected tissues was assessed by HPLC and normalized to HBSS values in order to 
determine Dox concentration.
2.2.4 Tumor Efficacy.
 The therapeutic efficacy of polyMPC-Dox was evaluated using a human ovarian 
tumor model in NOD SCID mice. Human ovarian tumors were established by injecting 
1x107 SKOV-3 cells subcutaneously in the right flanks of 24 four week old NOD SCID 
mice. Mice identified to have intramuscular tumors were excluded from analysis. Once 
tumors reached a volume of 250-500 mm3, mice were randomly divided into four 
treatment groups of 7-8 mice. Treatment groups included: HBSS (control), 2mg/kg free 
Dox (half of the reported Dox MTD in NOD SCID mice) [23], polyMPC-Dox at 5mg/kg 
Dox equivalent dosing (half of the polyMPC-Dox MTD dose), and 5mg/kg Doxil (Dox 
dose equivilant to polyMPC-Dox). Mice were administered treatment via lateral tail vein 
injections every 7-8 days. Treatment was withheld if the animals exhibited significant 
weight loss approaching 20% or excessive injection site wounds or scarring prohibiting 
further injections.Animals were evaluated every 24-48 hours for overall health, tumor 
volume and weight. Mice were removed from the study and euthanized if they 
experienced weight loss greater than 20%, exhibited signs of distress or if tumor volume 
exceeded 1500mm3. At time of euthanasia, necropsy was performed and tumors and 
organs (liver, kidneys, spleen, heart and lungs) were collected for histologic evaluation.
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2.2.5 Statistical analysis
 All graphs were were created and statistical analysis was performed using 
GraphPad Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).
2.3 Results
2.3.1 Maximum tolerated dose (MTD) of polyMPC.  
 For the entirety  of the study, the polymer was well tolerated at all doses with no 
physical or behavioral concerns for toxicity.  All mice treated with polymer exhibited 
weight gain similar to those of control mice (Fig 2.1A).  Histological evaluation of the 
heart, kidney, spleen and lungs resected from mice treated with polyMPC exhibited no 
differences from the organs of the control animals. Livers of mice administered polyMPC 
did exhibit an increase in lymphocyte concentration at higher polymer doses, however, 
these changes were minor and were observed with no corresponding effect on the health 
of the hepatocytes (Fig 2.1D).  
2.3.2 MTD of polyMPC-Dox Establishment. 
 Mice were unable to tolerate polyMPC-Dox at all doses following intraperitoneal 
administration secondary to weight loss and ill health necessitating euthanasia (Fig 2.1B). 
Mice administered PolyMPC-Dox intravenously at doses of 20-50 mg/kg experienced 
weight loss and required removal from the study by euthenasia.  However, mice treated 
with 10mg/kg polyMPC-Dox survived throughout the course of the study  period with no 
overt signs of systemic toxicity  observed (Fig 2.1C).  Histologic analysis of liver sections 
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of mice administered intravenous polyMPC-Dox demonstrated evidence of lymphocytic 
infiltration and hepatocyte enlargement otherwise no significant histologic changes were 
observed upon polyMPC-Dox treatment (Fig 2.1D). 
2.3.3 Biodistribution of PolyMPC-Dox in a human ovarian tumor model. 
 Three days after intravenous treatment of either polyMPC-Dox (Dox equivalent 
dose of 6mg/kg) or free Dox (6mg/kg), the mean tumor uptake of polyMPC-Dox and free 
Dox was 1120 ng/g and 567 ng/g of tissue, respectively. The accumulation of polyMPC-
Dox in solid tumors was nearly two-fold that of free Dox after a single injection, resulting 
in a significant difference of α=0.10 (p=0.064).  However, no significant differences were 
observed for polyMPC-Dox and free Dox accumulation in off-target organs.  
2.3.4 Tumor efficacy. 
 The efficacy of polyMPC-Dox was evaluated using NOD SCID mice with 
subcutaneously established SKOV-3 tumors. Following tumor establishment, one mouse 
from the polyMPC-Dox group was excluded due to formation of an intramuscular tumor 
which precluded accurate measurement of tumor volume. Mice administered HBSS alone 
and polyMPC-Dox received a total of eight doses. Mice treated with free Dox received 
6-7 doses of drug secondary to the development of ulcers in the tail at sites of drug 
infusion which prevented administration of drug. Mice treated with doxil were only able 
to tolerate 5-6 doses of drug given significant weight loss necessitating withholding drug 
administration or euthanasia (Fig2.3B). The mean weight of mice treated with polyMPC-
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Dox and free Dox increased similarly to the control group. In contrast, mice treated with 
doxil exhibited significant weight loss following drug administration (Fig 2.3C). By Day 
50, seven of eight control animals were euthanized due to excessive tumor growth and as 
a result, final treatments for all groups were administered at Day 53.
 Mice treated with polyMPC-Dox exhibited mean survival time of 79 days, almost 
twice that of the control mice of 47 days, 15 days longer than the mean survival of mice 
treated with free Dox (~64 days) and 40 days longer then mean survival of mice treated 
with doxil (~38.5 days) (Fig 2.3A).  Moreover, by Day 60, all control mice had been 
euthanized, 86% of the animals treated with polyMPC-Dox were still alive, 50% of the 
mice from the free Dox group had survived and only 38% of doxil treated mice remained 
alive. Overall survival of mice treated with polyMPC-Dox was 121 days, 35 days longer 
than the free Dox group  and 56 days longer then doxil treated mice.  Treatment with 
polyMPC-Dox reduced tumor growth compared to the free Dox and control groups. By 
day 49 the increase in mean tumor volume for HBSS and free Dox groups was 1991% 
and 1113% of the original tumor volume, respectively (Fig 2.3D) while the mean tumor 
growth in the polyMPC-Dox group was 440% at Day 49.  In contrast, the tumor volumes 
of mice treated with doxil exhibited minimal growth by day 49 (~84% of initial tumor 
volume).  
 Upon necropsy, the organs and tumors were weighed and evaluated for any gross 
changes and H+Es of the organs were further evaluated to assess for off target toxicities. 
Upon evaluation of the heart, mice treated with doxil were observed to have a 
significantly larger heart size in proportion to overall weight. Histologic evaluation of 
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heart sections for mice treated with free Dox, polyMPC-Dox as well as doxil showed 
evidence of minor myocyte eosinophilic bands. The lungs of mice treated with doxil were 
also noted to be significantly larger in proportion to the total animal weight. Upon 
evaluation of the lung tissue in mice treated with doxil, foamy cells present  within the 
lungs were observed which were not identified in other treatment groups. Differences 
were also noted between the proportional weights of the liver and kidneys of control mice 
in mice treated with polyMPC-Dox. Histological review of liver sections from mice 
treated with free Dox and polyMPC-Dox revealed evidence of enlarged hepatocytes, 
increased mitotic activity and lymphocytic infiltration.  
2.4 Discussion
 This work is the first reported evaluation of a polyMPC cancer prodrug in a 
human tumor model.  We have shown that the polyMPC construct is a safe scaffold for 
administration in vivo and therefore can be utilized for the creation of prodrugs, such as 
polyMPC-Dox. The performance of polyMPC-Dox was then compared to that of free 
Dox and doxil in a human ovarian tumor model to assess it’s toxicity, tumor 
accumulation properties, and therapeutic efficacy. PolyMPC-Dox treatment resulted in 
increased tumor uptake and improved survival compared to free Dox. Additionally, 
polyMPC-Dox was observed to be better tolerated then doxil, resulting in less systemic 
toxicity. 
 The maximum tolerated dose is the greatest  amount of drug that can be tolerated 
without evidence of toxicity. All mice tolerated administration of polyMPC throughout 
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the course of the study without any outward signs of weight loss or distress. Even mice 
treated with a cumulative 1600mg/kg (800mg/kg per dose) of polyMPC exhibited weight 
gain similar to that  of HBSS control. Treatment utilizing higher doses of polymer were 
unable to be performed given the high viscosity  of the solution at polymer doses required 
above 800mg/kg dosing. Upon gross inspection of internal organs following euthanasia, 
there were no obvious abnormalities observed. Only  the spleen and lung of mice treated 
with 800mg/kg polyMPC exhibited a significant increase of the total percent body weight 
of these organs. The livers of mice administered polyMPC exhibited an increase in 
lymphocyte concentration at higher polymer doses, however, these changes were minor 
and were observed with no corresponding effect on the health of the hepatocytes. This 
study revealed that polyMPC is non-toxic even at very high doses. Further, this work 
established the suitability of polyMPC as an injectable carrier for delivery  of many types 
of drugs.
 Previously it was observed that polyMPC-Dox was well tolerated in athymic nude 
mice at Dox equivalent doses greater than three-fold the reported MTD of 8 mg/kg for 
free Dox [14,22]. NOD SCID mice, however, are known to be uniquely sensitive to Dox 
[23], with systemic toxicity  to Dox observed at doses as low as 4 mg/kg. Given this, an 
MTD analysis of polyMPC-Dox was necessesary to re-establish the prodrug MTD 
specifically in NOD SCID mice. At a dose of 10mg/kg DOX equivalent polyMPC-DOX, 
mice were able to tolerate intravenous administration of the prodrug, although higher 
doses of polyMPC-Dox were not  tolerated. PolyMPC-DOX was not tolerated upon 
intraperitoneal administration, potentially secondary to a more acidic environment found 
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within the peritoneal fluid. This would result in disruption of the hydrazine linkage 
binding Dox to polyMPC, resulting in a bolused release of free drug greater then it’s 
MTD. Histologic analysis of liver sections of mice administered polyMPC-Dox 
intravenously did demonstrate evidence of lymphocytic infiltration and hepatocyte 
enlargement. However, as Dox treatment is commonly accompanied by hepatotoxicity, 
these changes are most likely attributed to Dox itself [24,25].  Therefore the estimated 
MTD of polyMPC Dox was an intravenous dose of 10mg/kg or lower in NOD SCID 
mice.
 The in vivo biodistribution of both polyMPC-Dox and free Dox was assessed in 
mice bearing human ovarian tumors, comparing drug accumulation in tumor tissue and 
off-target  organs.  Subcutaneous SKOV-3 tumors were established in the right flanks of 
NOD SCID mice, and single doses of free Dox, at 6 mg/kg, or polyMPC-Dox at a Dox 
equivalent dose of 6 mg/kg, were administered by tail vein injection. These selected 
doses were consistent with previous biodistribution analysis of polyMPC-Dox in a breast 
tumor model [15]. Three days after drug administration, mean tumor uptake of Dox was 
observed to be increased in mice treated with polyMPC-Dox compared to that  of free 
Dox treated mice. No significant differences were observed for prodrug and Dox 
accumulation in off-target organs. Improved drug uptake by mice treated with polyMPC-
Dox can likely  be attributed to the EPR effect or increased half life associated with 
polyMPC conjugation to Dox.
 The efficacy  of polyMPC-Dox for treating a human cancer was evaluated using a 
SKOV-3 ovarian tumor model. SKOV-3 tumors are Dox-resistant at dosing levels 
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tolerated by animals [3], and thus this model allows for evaluation of polyMPC-Dox in a 
challenging human tumor model. Approximately half the MTD was utilized for dosing of 
free Dox (2mg/kg) and polyMPC-Dox (5mg/kg Dox equivilant). This was performed in 
an attempt to minimize dose-limiting toxicity during the weekly dosing schedule 
designed to mimic current clinical dosing practice [19]. Doxil, an alternative formulation 
of Dox utilized clinical to treat a variety of cancers including ovarian cancer, is a 
liposomal formulation of Dox. In order to compare the efficacy  of polyMPC-Dox to an 
alternate Dox formulation (Doxil), both drugs were administered at a Dox equivalent 
doses (5mg/kg).   
 We observed that mice treated with polyMPC-Dox were able to tolerate more 
frequent administration of drug compared to free Dox or doxil treated mice. Mice treated 
with free Dox received between 12-14 mg/kg, mice treated with doxil received between 
25-30mg/kg and mice treated with polyMPC-Dox recieved a total of 40 mg/kg 
cumulative Dox over the course of this study. Further, multiple free Dox treated mice 
developed local wounds overlying the site of tail vein administration which prevented 
repeated drug administration. Only one mouse treated with polyMPC-Dox developed a 
ulcer at the site of tail vein injection. In contrast, mice treated with doxil displayed 
significant weight loss following drug administration approaching the 20% weight  loss 
cutoff necessitating euthanasia. Given the significant weight loss, additional drug 
administration were withheld in these mice. In comparison, no significant weight loss 
was observed in mice treated with HBSS, free Dox or polyMPC-Dox.
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 Mice treated with polyMPC-Dox displayed improved survival compared to other 
treatment groups. PolyMPC-Dox treated mice survived almost twice that of control and 
doxil treated mice and approximately  two weeks longer that of free Dox treated mice.   In 
addition to improved survival, treatment with polyMPC-Dox displayed a reduced rate of 
tumor growth compared to free Dox and control groups.  Tumors in mice administered 
HBSS or free Dox grew slowly  for 40 days, after which the tumor growth rate in both 
groups rapidly increased most likely secondary  to cessation of drug administration.  The 
rate of tumor growth in mice treated with polyMPC-Dox remained nearly stagnant for 
approximately 80 days well beyond the final drug administration. In contrast, mice 
treated with doxil did not exhibit  any enlargement of tumor growth. Despite minimal 
tumor growth, mice displayed significant weight loss and health issues, including hair 
loss and abnormal gait, necessitating euthanasia much earlier then other treatment groups. 
 To assess systemic toxicity, the organs of animals were evaluated histologically  to 
assess for tissue damage.  Upon evaluation of cardiac and lung tissues, we observed that 
doxil treated mice had a significantly larger proportional weight  of these organs. 
Histologic evaluation of heart  sections for mice treated with free Dox, doxil and 
polyMPC-Dox only showed evidence of myocyte eosinophilic bands indicative of 
ischemic changes in the cardiac tissue. Upon evaluation of the lung tissue, doxil treated 
mice were observed to have foamy cells present within the lungs, secondary to the 
presence of macrophages. These changes most likely are attributable to the development 
of cardiac injury resulting in pulmonary edema and inflammation.   
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 Differences were noted between the proportional weights of the livers upon 
treatment with free Dox and polyMPC-Dox were observed in which there was evidence 
of enlarged hepatocytes, increased mitotic activity  and lymphocytic infiltration indicative 
of hepatotoxic injury. These findings were even more striking within the liver sections of 
mice administered free Dox, which is consistent with the known hepatotoxic nature of 
Dox [24, 25]. The changes observed in liver tissue, therefore, are likely  attributable to 
Dox itself, and not the prodrug or polymer carrier. Moreover, given the serial 
administration of drug used in the efficacy study, accumulation of Dox in organs involved 
in drug clearance would be expected resulting in observed histologic changes. Further 
research is warranted to examine polyMPC-Dox clearance, especially under such 
treatment conditions that resemble current clinical regimens.
 Upon comparison of outcomes of the different treatment groups evaluated in the 
efficacy study, polyMPC-Dox was the best tolerated Dox formulation allowing for the 
most consistent administration of drug with minimal side effects. While comparable Dox 
doses were provided upon each dose of polyMPC-Dox or doxil provided, significant 
toxicities were observed both grossly and histologically  in mice treated with doxil that far 
outweigh the benefits of the the minimal tumor growth that it afforded.  As NOD SCID 
mice are exquisitely sensitive to Dox administration, it is possible that the liposomal 
based Dox resulted in a bolused release of Dox systemically  that exceeded the maximally 
tolerated dose of Dox in animals. In contrast, polyMPC conjugation may have allowed 
for a more gradual release and uptake within not just the tumor but off target organs, thus 
resulting in improved drug tolerance and less side effects. 
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2.5 Conclusion
 Through this work, we not only established the safety of the polyMPC scaffold 
for use in prodrug development but determined the efficacy of polyMPC-Dox prodrugs 
through evaluation of it’s effect upon treatment in a human tumor xenograft in vivo. 
PolyMPC itself was well-tolerated in NOD SCID mice, even at very high doses, 
demonstrating its utility as an injectable polymer.  Upon biodistribution analysis, Dox 
accumulation from polyMPC-Dox treatment  in the tumor tissue was nearly two-fold 
higher then that of free Dox, without observation of enhanced uptake in off-target organs. 
Toxicity and efficacy  studies demonstrated that polyMPC-Dox could be administered to 
mice at greater than twice the dose of free Dox without causing systemic toxicity. 
Ovarian tumor-bearing mice receiving weekly  prodrug dosing exhibited improved 
survival time and reduced tumor growth relative to free Dox treatment. Additionally, 
polyMPC-Dox treatments provided at the same Dox dose as doxil, was much better 
tolerated and resulted in less systemic toxicity despite reduced tumor growth observed in 
doxil treated mice. These results demonstrate the advantages of treating human ovarian 
tumors using the polyMPC-Dox prodrug, including enhanced tumor uptake with reduced 
off-target  toxicity, higher dosing capabilities, and improved therapeutic efficacy.  In vivo 
evaluation in human ovarian tumors suggests that the polyMPC-Dox prodrug is safer and 
more effective in the treatment of solid tumors compared to Dox or alternative Dox 
formulations such as doxil. Thus, this study demonstrates the viability of polyMPC-Dox 
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cancer therapy, and that a simple water-soluble polymer-drug conjugate is useful for 
improving drug delivery to tumors. 
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2.6 Figures
Figure 2.1. Maximal Tolerated Dose Evaluation of PolyMPC and PolyMPC-Dox A)PolyMPC 
MTD-Weight  change over time of NOD-SCID mice treated with intravenous administration of 
polyMPC scaffold, doses ranging from 50-800mg/kg polyMPC.   B)Intraperitoneal PolyMPC-
Dox MTD-Weight  change of NOD-SCID mice treated with intraperitoneal administration of 
polyMPC Dox, ranging from 10-50mg/kg polyMPC-Dox, over time. C)Intravenous PolyMPC-
Dox MTD-Weight change of NOD-SCID mice treated with intravenous administration of 
polyMPC-Dox, ranging from 10-50mg/kg polyMPC-Dox, over time. D) Representative H&E 
staining of liver sections of mice administered (A) HBSS, (B) 800 mg/kg polyMPC, and (C) 
polyMPC-Dox at a 10 mg/kg Dox equivalent dose. All error Bars indicate +/- SEM, arrows 
represent days of polymer or polyMPC-Dox administration. Images were taken at 20X 
magnification with 40X magnification inlay images. All scale bars represent 50 µm.
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Figure 2.2 Biodistribution Analysis of PolyMPC-Dox. Biodistribution results following a 
single injection of free Dox (6 mg/kg) or polyMPC-DOX (6 mg/kg Dox equivalent) in SKOV-3 
tumor-bearing mice.  Accumulation, expressed as ng Dox/g of tissue, was measured in tumors 
and major organs using HPLC.  Error bars represent ± the SEM.
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Figure 2.3 Evaluation of Efficacy of PolyMPC-Dox in Human Ovarian Tumor Model In 
Vivo. Efficacy results for SKOV-3 tumor-bearing mice treated with HBSS (control), free Dox (2 
mg/kg), polyMPC-Dox (5 mg/kg Dox equivalent dose) or doxil (5mg/kg) A) Survival curve B) 
Average survival days C) Percent  change in mean mouse weights D) percent change in mean 
tumor volumes.  Black=HBSS, Red=Free Dox, Blue=PolyMPC-Dox, Green=Doxil. Error bars 
represent ± SEM, *=p<0.05.
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Figure 2.4 Evaluation of the  In Vivo Cardiac Effects of PolyMPC-Dox Treatment A) 
Proportional heart weights at  time of euthenasia for NOD SCID mice, bearing subcutaneous 
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg).  B)Representative 
H&E staining of cardiac sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox 
(5 mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy 
study.  Error bars represent  ± SEM. ****=p<0.0001. Images were taken at  20X magnification 
with 40X magnification inlay images. Scale bars represent 50 µm.
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Figure 2.5 Evaluation of the  In Vivo Pulmonary Effects of PolyMPC-Dox Treatment A) 
Proportional lung weights at  time of euthanasia for NOD SCID mice, bearing subcutaneous 
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg).  B)Representative 
H&E staining of lung sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox  (5 
mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy study. 
Red circles represent  foamy cells likely indicative of lymphocytes within the lung. Error bars 
represent ± SEM. ****=p<0.0001. Images were taken at  20X magnification with 40X 
magnification inlay images. Scale bars represent 50 µm.
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Figure 2.6 Evaluation  of the  In Vivo Liver Effects of PolyMPC-Dox Treatment A) 
Proportional liver weights at time of euthanasia for NOD SCID mice, bearing subcutaneous 
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg).  B)Representative 
H&E staining of liver sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox  (5 
mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy study. 
Error bars represent  ± SEM. *=p<0.05. Images were taken at  20X magnification with 40X 
magnification inlay images. Scale bars represent 50 µm.
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CHAPTER 3 
TARGETED CHEMOTHERAPY UTILIZING MESENCHYMAL STEM CELLS 
LOADED WITH POLYMPC
This research was performed in close collaboration with Nicholas Panzarino. 
3.1 Introduction
 Limitations associated with conventional systemic administration of 
chemotherapeutics include off target drug effects that damage healthy tissue, thus 
constraining therapeutic agents to a narrow window and diminishing their efficacy. The 
therapeutic effect of cancer drugs is, in many  cases, improved by their conversion to pro-
drugs [1]. In principle, prodrugs transport the therapeutic agent in a nontoxic form 
through the bloodstream, thereby shielding the body from off target toxic effects and 
improving the therapeutic profile of the drug [2,3]. In addition, polymer prodrugs also 
improve drug delivery by  passive tumor targeting via the enhanced permeability and 
retention (EPR) effect, in which the fenestrated tumor vasculature preferentially traps and 
retains the polymer prodrugs within the tumor [4-6]. After reaching the tumor, the drug is 
released from the polymer by a variety of tunable mechanisms, such as hydrolysis and 
enzyme driven chemistry [7].
 Numerous examples of polymer pro-drugs exhibit improved pharmacokinetic and 
biodistribution profiles [1]. Nevertheless, challenges remain for passively targeted agents 
to overcome the physical defenses of solid tumors, including elevated interstitial and 
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hydrostatic tumor pressure [8-11]. These elevated pressures arise from irregular tumor 
vasculature [12], a disabled tumor lymphatic system [13], and the density of tightly 
packed cancer cells [14], collectively impairing drug penetration. Furthermore, the 
elevated pressures also impair uniform drug diffusion throughout the tumor, consequently 
exposing tumor regions to ineffective drug concentrations and limiting their therapeutic 
effect [15]. This represents a principle barrier to the efficacy of passively  administered 
agents, and may also facilitate the development of drug resistance in solid tumors [13].
 MSCs are a pluripotent progenitor cell type which are most abundant in bone 
marrow and adipose tissue. MSCs differentiate into adipocytes, chondrocytes, and 
osteoblasts, and have been observed to migrate to sites of injury  and to promote wound 
healing. MSC specific migration holds potential for the treatment of damaged tissues 
resulting from myocardial infarction and stroke, as well as for delivering secreted 
therapeutic proteins to wounds [16].
 MSCs have been reported to actively migrate to solid tumors and therefore hold 
potential to actively transport therapeutic agents directly to tumors in order to overcome 
their physical tumor defenses [17]. Use of MSCs in cancer therapeutics may ultimately 
improve drug targeting, increase drug penetration, and reduce off target toxicities. Such 
an approach has been evaluated previously  as MSCs transduced to produce interferon β 
reduced tumor growth in melanoma bearing mice [15].  Subsequent studies have 
delivered a wider range of biologics or nanoparticles as a strategy to transport 
chemotherapeutics agents to tumors utilizing MSCs [18-25]. For example, Zhang et al., 
loaded MSCs with doxorubicin (Dox) polymer conjugates which were intracranially 
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injected into mice with glioma xenografts. Mice treated with MSCs carrying Dox 
polymer conjugates experienced prolonged survival compared to control animals [25]. 
However, the therapeutic potential of drug loaded MSCs administered systemically  has 
yet to be evaluated.
3.2 Materials and Methods
3.2.1 Cell culture. 
 Human bone marrow mesenchymal stem cells (Cell Engineering Technologies, 
(CET), Coralville, IA) were cultured in CET Mesenchymal Stem Cell Expansion 
Medium (CET, Coralville, IA) without phenol red. MDA MB-231 breast cancer cells and 
DO11.10 T-cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, Thermo 
Fisher, Grand Island, NY). All media was supplemented with 10% fetal bovine serum, 
100U/mL penicillin and 100µg/mL streptomycin (Thermo Fisher, Grand Island, NY) and 
cells were grown at 37°C and 5% CO2. 
3.2.2 Polymer loading into MSCs. 
 Polymer loading was carried out with 1x106 cells per mL in Live Cell Imaging 
Solution Physiological Buffered Saline (LCIS, Thermo fisher, Grand Island, NY) 
suspension containing 10µM polymer solution of polyMPC-Rhodamine B (RhdB), 10µM 
doxorubicin (Dox) equivilant polyMPC-Dox or 10µM free Dox at 37°C for 15 minutes. 
Cells were centrifuged at 200 x g for five minutes at 37°C and the pellet  was washed with 
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LCIS to remove unbound polymer. Polymer uptake was confirmed with confocal 
microscopy. 
3.2.3 Cell viability. 
 Cell viability was evaluated using trypan blue exclusion performed on a Beckman 
Coulter Vi-Cell Cell Viability  Counter (Beckman Coulter, Brea, Ca). Viability  was 
determined after polymer loading on MSCs with either polyMPC-RhdB or polyMPC-
Dox daily for up to 72 hours following polymer loading. Qualitative cell viability was 
evaluated for up to 96 hours following polymer loading by transmitted light  differential 
interference contrast images utilizing live cell confocal microscopy.
3.2.4 Co-culture Experiment. 
 Drug release from MSCs was evaluated utilizing T-cell viability as a marker for 
Dox release as T-cell viability  is exquisitely sensitive to the presence of Dox. T-cells were 
cultured with MSCs loaded with Dox or polyMPC-Dox. The viability of T-cells was 
evaluated over 72 hours utilizing trypan blue exclusion with a Beckman Coulter Vi-cell 
Viability Counter.
3.2.5 Evaluation of PolyMPC loaded MSC in vivo migration. 
 Non-obese diabetic severe combined immunodeficient (NOD SCID) mice were 
implanted with 1X107 MDA MB-231 breast cancer cells in the right lateral flank. When 
tumor volumes (calculated by tumor length X tumor width2)/2) grew to a minimum of 
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500 mm3, mice were administered HBSS or 100,000-500,000 MSCs loaded with 
polyMPC-RhdB provided via lateral tail vein injection. Five days following injection, the 
mice were euthanized. Tumors were divided and sections were either flash frozen in 
liquid nitrogen or formalin fixed and subsequently paraffin embedded.
3.2.6 Evaluation of polymer loaded MSC migration to tumor. 
 Frozen tumor sections embedded in optimal cutting temperature (OTC) 
compound were cut at 4 µm thickness. Tumor sections were first imaged for RhdB 
fluorescence to detect for the presence of polyMPC-RhdB loaded MSCs. Images for 
polyMPC-RhdB were captured with a Nikon Eclipse Ti microscope equipped with an 
Xcite Mercury Arc lamp and a Texas Red HyQ filter set (Nikon). 
 Immunohistochemistry (IHC) was performed on a Dako Cytomation autostainer 
using the Envision HRP Detection system (Dako, Carpinteria, CA) following paraffin 
embedding of formalin fixed tumor samples to evaluate for human CD105 (Ab169545, 
Abcam, Cambridge, MA), specific to human bone marrow MSCs. Each mammary tissue 
block was sectioned at 4µm on a graded slide, deparaffinized in xylene, rehydrated in 
graded ethanols, and rinsed in Tris-phosphate-buffered saline (TBS). Heat induced 
antigen retrieval was performed in a microwave at 98ºC in 0.01M citrate buffer. After 
cooling for 20 minutes, sections were rinsed in TBS and subjected to an antibody  specific 
for human CD105 at 1:400 dilution for 45 minutes. Immunoreactivity was visualized by 
incubation with chromogen diaminobenzidine (DAB) for 5 minutes. Tissue sections were 
counterstained with hematoxylin, dehydrated through graded ethanols and xylene, and 
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cover-slipped. Images were captured with an Olympus BX41 light microscope using 
SPOT™Imaging Solutions (Detroit, MI).
3.2.7 Statistical Analysis
 All graphs were created and statistical analysis was performed utilizing GraphPad 
Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).
3.3 Results
3.3.1 PolyMPC-RhdB and PolyMPC-Dox Polymers are Stably Loaded onto MSCs.  
 Following incubation of MSCs with polyMPC-RhdB, no reduction in viability was 
observed up to 72 hours following treatment (Fig 3.1C). Further, no reduction in viability 
was observed upon loading of MSCs with polyMPC-Dox as well (Fig 3.1D).  Confocal 
microscopy revealed a distinctive filamentous pattern of cytoplasmic fluorescence with 
sparing in the nucleus observed in both polyMPC-RhdB and polyMPC-Dox (Fig 3.1B) 
loaded MSCs. This pattern of florescence was observed to be stable for up to 96 hours. In 
contrast, MSCs loaded with Dox exhibited a diffuse pattern of fluorescence (Fig. 3.1A)  
3.3.2 MSC Co-Culture Experiment
 Drug release from MSCs was evaluated utilizing T-cell viability as a marker for 
Dox release, given exquisite T-cell sensitivity  to Dox. Co-culture of T-cells with MSCs 
loaded with Dox led to a reduction in T-cell viability over 72 hours (Fig 3.2A). In 
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contrast, MSCs loaded with polyMPC-Dox did not lead to appreciable T-cell death (Fig 
3.2B).
3.3.3 PolyMPC-RhdB Loaded MSCs Home to Tumors In Vivo. 
 Mice with established subcutaneous human mammary tumor (MBA MB-231) 
xenografts were treated with polyMPC-RhdB loaded MSCs. Five days after the MSCs 
were administered, mice were euthanized, necropsy was performed and tumors were 
evaluated in order to determine if MSCs had transported their polymer cargo to the solid 
tumors. Frozen tumor sections imaged for RhdB fluorescence to detect for the presence 
of MSCs containing polyMPC-RhdB revealed distinct fluorescent foci present throughout 
the tumor sections. In contrast, tumors from mice treated with saline were not fluorescent 
(Fig 3.3). Immunohistochemistry  (IHC) was performed on paraffin-embedded tumor 
sections using a human CD105 antibody specific for human MSCs. We observed anti-
CD105 antibody to stain tumor sections from mice treated with polyMPC-RhdB loaded 
MSCs while negligible staining was observed in the saline control tumors (Fig. 3.3). 
3.4 Discussion
 While a wide variety of treatment options are available for the treatment of 
cancer, therapy is often limited by  the toxicities associated with these chemotherapeutic 
agents. Means to improve drug targeting directly to tumors can result in increased uptake 
of the drugs into the tumor as well as reduced uptake in other off target organs. 
Conjugation of these drugs to polymers, such as polyMPC, can allow for passive 
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targeting of the tumor through the enhanced permeability and retention (EPR) effect [26, 
27]. Delivery  of these prodrugs can be further improved through utilization of a more 
active and targeted method.  Here, we evaluated a cellular tumoritropic vehicle for 
polymer drug delivery through utilization of MSCs. 
 MSCs were able to stably uptake both polyMPC-RhdB and polyMPC-Dox. For 
this work, Rhodamine B (RhdB) bound to polyMPC was utilized in addition to 
polyMPC-Dox because RhdB’s brighter fluorescence allowed for a facile analysis of 
cellular uptake. Following incubation of MSCs with polyMPC-RhdB, no reduction in 
viability  was observed for up to 72 hours following treatment. Repeat analysis utilizing 
polyMPC-Dox also revealed stable uptake. Confocal microscopy  confirmed uptake of 
both polymers without altering viability  for upto 96 hours. Compared to free Dox, both 
polyMPC-RhdB and polyMPC-Dox exhibited a filamentous pattern of fluorescence 
throughout the cytoplasm consistent with intracellular localization within the 
mitochondria. In constrast, free Dox uptake within MSCs was noted to be diffuse 
throughout both the cytoplasm and nucleus.
 Drug release from MSCs was evaluated utilizing T-cell viability as a marker for 
Dox release, given exquisite T-cell sensitivity to Dox. Co-culture of T-cells, a 
suspensatory cell line, with MSCs, an adherent cell line, which were loaded with Dox led 
to a reduction in T-cell viability over 72 hours. This provided evidence that MSCs can not 
only be loaded with Dox, but can also release the drug. In contrast, MSCs loaded with 
polyMPC-DOX did not lead to appreciable T-cell death. It remains unclear this difference 
in outcome is secondary to reduced drug uptake or reduced drug release by the MSCs. 
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 Following the observation that MSCs can be stably loaded with polyMPC- Dox 
and have the potential for drug release in vitro, the in vivo migratory  capabilities of 
polymer loaded MSCs was evaluated. We observed that MSCs containing their polymer 
cargo maintained their tumoritropic abilities. MSC lmigration was evaluated both with 
fluorescent microscopy to evaluate for the presence of polyMPC-RhdB as well as through 
IHC to assess for human cd105, which is specific for MSCs. Together, fluorescent 
imaging and IHC confirmed that systemically administered MSCs actively  transport to a 
solid tumor while loaded with polymer cargo. This suggests that  MSCs can serve as 
vehicles for actively targeted delivery of drugs, including polyMPC prodrugs.
3.5 Conclusion
 In summary, cellular vehicles with inherent tumoritropic properties, such as 
MSCs, provide the unique ability to actively target and deliver chemotherapeutic drugs to 
tumors. This potentially allows for improved efficacy and reduced off target toxicity. We 
found that polyMPC can be stably loaded into MSCs and that the cells maintain their 
tumoritropic capabilities and can migrate to established tumor xenograft upon systemic 
administration in vivo.  This work provides evidence that MSCs hold potential to improve 
active tumoral drug delivery of polymer prodrugs and future work will focus on drug 
release and therapeutic efficacy of drug loaded MSCs.   
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3.6 Figures
Figure 3.1 MSC Drug Uptake and Viability. A) Live cell confocal microscopic image (63X) of 
MSCs loaded with Dox B) Live cell confocal microscopic image (63X) of MSCs loaded with 
PolyMPC-Dox. C)Viability of polyMPC-RhdB loaded MSCs evaluated by trypan blue exclusion. 
Red=polyMPC-RhdB MSCs, Black=untreated MSCs. D) Viability of polyMPC-Dox loaded 
MSCs evaluated by trypan blue exclusion. Green=polyMPC-Dox MSCs, Black=untreated MSCs. 
Error bars represent standard deviation.
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Figure 3.2 MSC Co-culture Experiment. A) 72 hour viability analysis, evaluated by trypan blue 
exclusion, of T-cells (DO11.10) grown in either MSC conditioned media (red), 1uM FD (dark 
blue), co-culture with MSC loaded DOX (blue) or with DOX loaded MSC conditioned media 
(light  blue). B) 72 hour viability analysis, evaluated by trypan blue exclusion, of T-cells grown in 
either MSC conditioned media (red), 1uM DOX equivalent polyMPC DOX (dark green), co-
culture with MSC loaded with polyMPC-DOX (green) or with polyMPC-loaded MSC 
conditioned media (light green).
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Figure 3.3 Polymer Loaded MSC Tumor Homing In Vivo A) Left: Fluorescent microscopic 
images (10X) of RhdB fluorescence from a frozen tumor section from a mouse treated with 
polyMPC-RhdB loaded MSCs. Right: Microscopic images (20X) of a paraffin embedded tumor 
section from a mouse treated with polyMPC-RhdB loaded MSCs immunohistochemically stained 
with human CD105. B) Fluorescent  microscopic images (10X) of RhdB fluorescence from a 
frozen tumor section from a mouse treated with saline. Right: Microscopic images (20X) of a 
paraffin embedded tumor section from a mouse treated with saline immunohistochemically 
stained for human CD105. Scale bars for all images represent 50uM
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CHAPTER 4 
EVALUATION OF RHODIOLA CRENULATA ON THE TREATMENT OF 
MELANOMA
This research was performed in close collaboration with Maxine Dudek and Dr. Carmen 
Mora. 
4.1 Introduction
 Each year, more than 76,000 people in the United States are diagnosed with 
melanoma, the most aggressive form of skin cancer [1]. Melanoma arises from the 
malignant transformation of melanocytes. Melanocytes specialize in melanogenesis or the 
production of melanin, a pigment that protects the skin by absorbing and scattering 
harmful solar radiation [2]. During the development of melanoma, mutated melanocytes 
display  rapid proliferation and growth. Melanomas that grow laterally or display a radial 
growth phase (RGP) pattern are typically  less aggressive than those displaying a vertical 
growth phase (VGP) pattern [3]. At present, primary  cutaneous melanomas are staged 
according to their thickness or vertical growth. With increasing T stage category, 
cancerous cells are more likely  to invade into through the basement membrane resulting 
in an increased risk of metastatic spread [4-6]. Given its aggressive behavior the five year 
survival rate for patients diagnosed with metastatic melanoma is less than 16% [1].
 At present, early detection of melanoma is the most important means to improve 
disease survival. Primary treatment involves surgical resection, brachytherapy, targeted 
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molecular therapy, and/or immunotherapy. Despite these aggressive interventions, 
treatment options for patients with metastatic disease remain limited and typically is 
associated with a poor prognosis. Consequently, investigations into novel treatment 
options are necessary for patients with this aggressive disease. One promising treatment 
option is the extract derived from Rhodiola crenulata (RC) plant roots. RC is a small 
perennial plant cultivated in barren soils and high altitudes in the tundra regions of 
Siberia and the highlands of Tibet. Traditionally, the phenolic phytochemicals extracted 
from the root of RC have been used to treat disorders such as depression, anxiety, and 
fatigue [7-10]. Recent studies have demonstrated the therapeutic potential of RC in a 
variety of malignancies including bladder cancer, breast cancer, and glioblastoma 
[11-14]. Given the anti-tumorigenic properties observed with the use of Rhodiola plant 
extracts both in vitro and in vivo, this current study was designed to evaluate the 
therapeutic potential of RC root extract on a melanoma cell line. 
4.2. Materials and Methods
4.2.1 R. crenulata Preparation. 
 RC root extract was obtained in powdered form from Barrington Chemical 
Corporation (Harrison, NY). For cell culture and oral administration experiments, RC 
powder was dissolved in a 10% ethanol solution in distilled water and was filter 
sterilized. Cream-based RC for topical experiments was prepared by the addition of 5% 
or 10 % RC by weight to a 10% DMSO-Eucerin™-based cream.
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4.2.2 Cell Culture. 
 B16-F10 (CRL-6475™) murine melanoma cell culture line was obtained from 
ATCC® (Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/
mL streptomycin (Thermo Fisher, Grand Island, NY) at 37°C under 5% CO2.
4.2.3 Evaluation of viability and proliferation. 
 A CellTiter96® Aqueous One Solution MTS Assay  (Promega, Madison, WI) 
assay was performed according to the manufacturer’s directions in order to test for cell 
growth and proliferation. A total of 5X103 B16-F10 cells were seeded on a 96-well 
microtiter plate and treated with 200 µg/mL RC or ethanol vehicle control and assay was 
performed in quintuplicate. After incubation for 24, 48, and 72 hours following treatment, 
the plate was spun at 2000 X g for one minute, treated media was decanted and replaced 
with 100µL of 1X PBS with 20 µL of MTS reagent per well. The plate was then 
incubated at 37°C in a humidified, 5% CO2 atmosphere for three hours. The absorbance 
of each well was recorded at 490 nm using an Enspire® multimode automated plate 
reader (PerkinElmer, Waltham, MA).
4.2.4 Clonogenecity assay. 
 A total of 200 B16-F10 cells were seeded onto 60-mm tissue culture plates. After 
allowing the cells to adhere for 24 hours, plates were treated with 100 µg/mL RC or 
vehicle control for 1 hour +/- exposure to 5 Gy radiation or sham treatment. The media 
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was replaced with appropriate treatment every  four days. On day  11, colonies were fixed 
in methanol and stained with 2% crystal violet in a 50% methanol solution. Colonies 
were defined as a cluster of five or more cells. The number of colonies were quantified 
visually and compared between treatment groups. The experiment was performed in 
triplicate.
4.2.5 Migration assay
 Migration and cell growth were evaluated using a scratch wound assay. B16-F10 
cells were plated on 30-mm dishes and allowed to reach 100% confluency  and then a 
scratch was made down the center of each culture with a pipette tip. Plates were then 
treated with 100 µg/mL RC or ethanol vehicle control, and cell growth was monitored 
over 48 hours. Images of the plates were captured daily with Nikon Eclipse TE2000-U 
using Metaview™ software (Universal Imaging Corporation). 
4.2.6 Evaluation of Topical RC Therapy on a Subcutaneous Melanoma In Vivo.
 Thirty 8-week-old virgin C57BL/6 female mice were housed in plastic cages and 
were permitted free access to food and water. A total of 1X106 B16-F10 cells were 
implanted subcutaneously above the scapular fat pad. Daily  topical RC treatment was 
initiated 24 hours following tumor implantation. Treatment groups (10 animals/group) 
included the following: 5% RC cream, 10% RC cream, and DMSO control cream. Mice 
were evaluated daily, and tumor volume measurements were obtained once tumors 
became palpable. Tumor volume was calculated by (tumor length X tumor width2)/2, in 
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which the tumor width was the smaller of the two measured values. Mice were 
euthanized if they appeared to be in any distress, exhibited greater than 15% weight loss, 
or when tumor volume exceeded 1500 mm3. Upon euthanasia, necropsy was performed, 
and tissues were preserved in 10% formalin. Excised tumors were paraffin embedded and 
stained with hematoxylin and eosin (H&E, Poly Scientific, Bay Shore, NY). The total 
number of mitotic cells was quantified in three representative images at  40X power per 
tumor sample obtained from each mouse in the DMSO and 10% RC treated groups. 
Images were captured with an Olympus BX41 light microscope using SPOTSOFTWARE 
(Diagnostic Instruments, Inc.).
4.2.7 Evaluation of Enteral RC Therapy on a Subcutaneous Melanoma In Vivo.
 Subcutaneous B16-F10 tumors were established overlying the scapula of 20 
C57BL/6 mice. Beginning 24 hours prior to tumor implantation, drinking water of ten 
mice per treatment group was supplemented with either 50mg/kg RC or ethanol vehicle 
control. Mice were evaluated daily, and tumor volume measurements were obtained once 
tumors became palpable. Tumor volume was calculated by (tumor length X tumor 
width2)/2, in which the tumor width was the smaller of the two measured values. Mice 
were euthanized if greater then 15% weight loss was observed, tumor volume exceeded 
1500mm3 or mice exhibited any signs of distress. Necropsy  was performed at time of 
euthanasia. Outcomes, including length of survival and tumor growth were compared 
between treatment groups.
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4.2.8 Evaluation of RC to Prevent the Establishment of Metastatic Melanoma In Vivo
 Sixteen 8-week-old C57BL/6 female mice were pretreated for three days with 
100mg/kg RC or vehicle supplemented water (8 mice/group). A total of 1X105 B16-F10 
cells were injected via lateral tail vein to model a disseminated disease state. Mice were 
evaluated daily, and water was replaced with appropriate treatment every 48 hours. Mice 
were euthanized if they appeared to be in any distress or exhibited more than 15% weight 
loss. All surviving mice were euthanized 30 days following tumor injection. At the time 
of euthanasia, the lungs were preserved in Fekete’s solution [15], while remaining organs 
were preserved in 10% formalin. The lungs were evaluated for gross establishment of 
metastatic foci, and photos were obtained of gross lung specimens. Formalin-fixed 
paraffin-embedded lungs were further analyzed histologically  by  H&E staining. 
Representative images of H&E-stained lung sections were taken using an Olympus BX41 
light microscope using SPOTSOFTWARE (Diagnostic Instruments, Inc.).
4.2.9 Statistical analysis
 All results were analyzed using either a two-tailed student’s t-test with one-way 
analysis of variance (ANOVA) or a two-ANOVA with a Bonferroni’s correction. 
Statistical outliers were identified utilizing a rout test [16]. All graphs were created and 
statistical analysis was performed using GraphPad Prism Software (Prism, GraphPad 
Software, Inc., San Diego, CA).
4.3. Results
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4.3.1 RC induces morphological changes in B16-F10 cells. 
 B16-F10 cells are typically adherent, flat, and have multiple dendritic projections. 
Upon treatment of these cells with increasing doses of RC, we observed phenotypic 
changes at doses greater than 200 µg/mL RC. Cells treated with RC exhibited reduced 
dendritic projections, became rounder, and were less adherent (Fig 4.1A). 
4.3.2 RC decreases B16-F10 proliferation
 To assess RC’s effect on growth and proliferation, we performed an MTS assay on 
B16-F10 cells treated with either RC (200 ug/mL) or vehicle control. Following 24 hours 
of treatment an initial trend toward decreased proliferation was observed in RC treated 
cells. By  48 and 72 hours, a significant reduction in proliferation was observed upon RC 
treatment (p<.01 and p<.0001, respectively, Fig. 4.1B).
4.3.3 RC Decreases Colony Formation of B16-F10 Cells
 To evaluate RC treatment efficacy, a clonogenecity assay was performed. RC 
treatment significantly reduced the number of colonies established (p<.001) compared to 
vehicle control (Fig. 4.1C). However, radiation sensitivity  did not appear to be enhanced 
by treatment with RC. 
4.3.4 RC Decreases Cellular Migration of B16-F10 Cells
 To determine if RC affects migration of B16-F10 cells, a scratch wound assay  was 
performed. Cultures treated with vehicle control exhibited complete wound closure by 48 
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hours, while cells treated with RC maintained distinct wound boundaries with minimal 
growth at 48 hours (Fig 4.1D). 
4.3.4 Evaluation of the Topical RC treatment on subcutaneous B16-F10 Tumors In Vivo
 A trend toward increased survival was observed in mice treated with RC. Mice 
treated with 5% RC and 10% RC met requirements for euthanasia by days 15 and 20, 
respectively, while mice treated with vehicle met requirements for euthanasia by 14 days 
(Fig 4.2A). Further, one mouse treated topically with 5% RC exhibited complete 
regression of the subcutaneous tumor and survived for over 30 days. There was no 
difference in the final weights of mice at the time of euthanasia (Fig 4.2C). While no 
significant difference was observed in the overall size of the measured tumor volume (Fig 
4.2B, D), tumors in mice treated with vehicle control tended to be raised, while animals 
treated with RC displayed a more horizontal growth pattern (Fig 4.3A).   Additionally, 
tumors treated with RC exhibited a significantly  lower number of active mitotic figures 
per high power field compared to the vehicle-treated mice (Fig 4.3C, D, p=.0374). 
4.3.5 Evaluation of the Enteral RC treatment on subcutaneous B16-F10 Tumors In Vivo
 Similar to the topical RC experiments, there was no signficant difference 
observed in the survival and tumor growth in mice treated with RC enterally compared to 
vehicle control (Fig 4.4A). At the time of euthanasia, there was no difference in the 
weight of the mice, tumor volume or tumor weight (Fig 4.4 B, C, D respectively). 
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Additionally, there were no gross difference in tumor growth patterns observed amongst 
treatment groups. 
4.3.6 Evaluation of Enteral RC to Prevent Establishment of Metastatic Melanoma
 Upon necropsy performed 30 days following tumor injection, a striking difference 
in the tumor establishment within the lungs was observed. Mice treated with RC 
exhibited a reduction in tumor burden established in the lungs compared to mice treated 
with ethanol vehicle control (Fig 4.5A). No other organs bore a similar difference in 
tumor establishment. Total lung weights confirmed our gross findings, in which there was 
a significant decrease in the weight of lungs treated with RC compared to vehicle control 
(Fig 4.5B, p<0.05). Additionally, histologic examination of the lungs confirmed reduced 
establishment of tumor foci in animals treated with RC.
4.4 Discussion
 Melanoma is the most aggressive and deadliest form of skin cancer. The SEER 
database estimated that melanoma was responsible for the death of more than 9,000 
Americans in 2015 [1]. Currently, prevention and early detection are the best  methods to 
reduce the mortality rate associated with melanoma. Unfortunately, effective treatment 
options for cases of advanced and disseminated disease remain limited. Consequently, 
there may be significant value in identifying natural products that possess potent 
anticancer properties. Rhodiola plant extracts have exhibited a number of anti-
tumorigenic properties in a variety of cancers and have been shown to promote cell death 
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and inhibit both proliferation and angiogenesis within a variety  of cancers [11,12,14,17]. 
Based on the data presented above, RC extract, and the compounds contained within it, 
may represent a potentially novel and effective melanoma therapy.
 In this study, we evaluated the effect  of RC on an aggressive melanoma cell line, 
B16-F10. Upon treatment with RC in vitro, B16-F10 cells exhibited morphological 
changes, reduced proliferation, increased cell death, and reduced colony formation 
compared to vehicle controls. Given the promising effects observed with RC treatment 
upon melanoma cells in vitro, investigation of the therapeutic effects of this extract were 
then evaluated in vivo.
 While no overt difference in the survival and tumor growth in mice with 
subcutaneous tumors treated with RC were observed, differences in growth patterns and 
mitotic activity was observed in tumors treated with topical RC. Upon topical RC 
treatment, tumors displayed more horizontal growth patterns while the tumors of vehicle 
control treated mice tended to grow more vertically. Of note, the endpoint for the 
investigation of RC treatment of subcutaneous tumors was based on the length and width 
of the pigmented area, but not on the vertical axis in tumor volume measurements. If the 
vertical axis had been a consideration, then the overall survival time of RC-treated 
animals compared to vehicle control-treated animals may have resulted in a significant 
improvement in survival. The differences in growth patterns observed is critical as 
melanoma displaying radial growth patterns are associated with considerably lower rates 
of metastatic disease compared to the more aggressive and vertically growing 
phenotypes.
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 Upon further histologic analysis of tumor sections, topical RC treated tumors 
displayed reduced mitotic activity. High mitotic rates in cutaneous melanomas are known 
to be associated with more aggressive disease phenotypes and significantly  lower 
survival rates [19-23]. Therapeutic agents that reduce the mitotic rates of melanomas 
have the potential to reduce tumor growth and improve overall survival. This further 
suggests that RC can reduce the aggressive potential of melanoma tumors in vivo. 
 Topical application of RC creams resulted in phenotypic changes in the tumor that 
are associated with less aggressive behavior. While RC has previously been used 
topically to reduce the size of pigmented lesions [24], this work is the first to suggest that 
the RC is bioactive when applied topically in the setting of a cutaneous neoplasm. In 
contrast, enterally administered RC did not result  in any changes in tumor growth or 
histologic characteristics. While RC has previously  been shown to be bioavailable upon 
enteral administration in the setting of other cancers, there are several reasons as to why 
RC administered topically was more effective then enterally  administered RC in this 
study. First, RC doses provided enterally may may have lead to poor tumor uptake while 
topically administered RC may  have lead to more concentrated uptake within the tumor 
bed directly. Additionally, B16-F10 melanoma is a syngeneic line with C57BL/6 mice, 
resulting in very aggressive growth and dissemination following tumor implantation. As 
such, tumor growth may have exceeded the ability  to observe any  efficacious changes 
following RC treatment administered enterally. 
 Upon in vivo evaluation of RC treatment in a disseminated model of melanoma,  a 
dramatic reduction in the establishment of metastatic foci in the lungs was observed. 
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Given this, RC’s ability  to prevent establishment of metastatic disease is very  promising 
as a novel therapy for melanoma. The molecular detection of circulating tumor cells in 
patients with melanoma has been established as a negative prognostic indicator, 
emphasizing the impact of hematogenous spread on overall survival [25, 26]. Current 
treatments for locally or regionally  advanced disease, such as interferon, provide only 
minimal improvements in patient survival. Treatments that may further prevent the 
development of metastatic lesions, such as RC, can potentially be utilized as an adjunct to 
other chemotherapeutic agents to prevent further dissemination of the disease. 
4.5 Conclusion
 In summary, treatment of B16-F10 melanoma with RC resulted in promising anti-
neoplastic properties noted both in vitro and in vivo. We observed that RC was cytotoxic 
to melanoma cells and reduced cell proliferation and migration in vitro. We also observed 
that topical RC could impede more aggressive vertical growth characteristics of tumors 
critical for the establishment of metastatic disease. Furthermore, our findings demonstrate 
the potential anti-metastatic activity of this extract when utilized in a disseminated model 
of melanoma. The identification of novel agents with chemotherapeutic potential, such as 
RC, is important for the improvement of overall patient survival. Thus, Rhodiola plant 
extracts may have a place in the future as an adjuvant therapeutic agent for the treatment 
of melanoma.
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4.6 Figures
Figure 4.1 In Vitro  Effects of RC  treatment upon Melanoma A) Phase contrast image 
representation of B16-F10 cells treated for 72 hours with 100 µg/mL R. crenulata or ethanol 
vehicle. B) MTS assay performed on cells treated with Rhodiola or vehicle control evaluated at 
24, 48 and 72 hours. C) Clonogenicity assay performed on cells treated with either Rhodiola on 
vehicle control with or without  exposure to 5 Gy radiation. All colonies containing more then five 
cells that  grew following 8 days of therapy were quanitified. D) Scratch wound healing assay 
performed on a confluent  monolayer of cells treated with either Rhodiola or vehicle control. 
Scratch wound healing was observed at  15 minute, 4, 24 and 48 hour time intervals. All images 
were obtained at 20X magnification. Error bars represent ± standard error of the mean. *=p<0.05, 
***=p<0.001, ****=p<0.0001.
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Figure 4.2 Outcomes of Topical  RC  Treatment of Melanoma In Vivo. A) Survival Curve of 
C57BL/6 mice with B16-F10 subcutaneous tumors treated with topical DMSO cream (red), 5% 
RC (dark blue) and 10% RC (light  blue). NS=non-signficant. B) Change in tumor growth over 
time among treatment groups including DMSO cream (Dark blue), 5% RC cream (dark purple) 
and 10% RC (light purple). C) Average mice weight at time of euthaniasia. D) Tumor weight  (g) 
at time of euthanasia. Error bars indicate ± standard error of the mean.
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Figure 4.3 Gross and Pathological  Changes upon Topical RC Treatment of Melanoma. A) 
Photographic representation of tumors treated topically with 5% or 10% R.crenulata cream or 
vehicle cream. B) Image representation of histological tumor specimens stained with hematoxylin 
and eosin. Red arrows indicate mitotic cells. Images were captured at 40X magnification. C) 
Average number of mitotic cells present  within each representative 40X field and compared 
between mice treated with vehicle cream and 10% Rhodiola cream. Error bars represent ± 
standard error of the mean, *p<0.05.
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Figure 4.4  Outcomes of Enteral RC Treatment of Melanoma In Vivo. A) Survival Curve of 
C57BL/6 mice with B16-F10 subcutaneous tumors treated with enteral 50mg/kg RC or ethanol 
vehicle control. B) Mouse weight (g) at time of euthanasia comparing ethanol treated (blue) to 
RC treated (yellow). C) Tumor volume at  time of euthanasia. D) % Total body weight of tumor 
compared to total mouse weight at time of euthanasia. Error bars indicate ± standard error of the 
mean.
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Figure 4.5 Effects of Enteral RC Treatment on the  Establishment of Metastatic Melanoma 
A) Photographic representation of lungs of C57BL/6 mice at 30 days following disseminated 
B16-F10 tumor administration via lateral tail vein injection in mice treated with ethanol 
supplemented water or 100mg/kg RC supplemented water B) Lung weight (g) at time of 
euthanasia of mice treated with ethanol or 100mg/kg RC, ROUT Test was performed to identify 
statistical outliers. Error bars indicate ± standard error of the mean, *=p<0.05. 
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CHAPTER 5
EVALUATION OF RHODIOLA CRENULATA ON THE TREATMENT OF 
NEUROBLASTOMA
5.1 Introduction
 Neuroblastoma is the most common extra-cranial solid malignancy in infants and 
children. Occurring in approximately 1 in 100,000 children, neuroblastoma is responsible 
for 15% of all pediatric cancer deaths [1-4].  While these tumors of neurocrest origin may 
arise anywhere along the sympathetic ganglion chain, they  most  commonly arise from the 
adrenal medulla[1].  The clinical course of this highly malignant neoplasm is quite 
variable depending on the location of the primary tumor, age of the patient, and stage of 
disease at presentation. The DNA content of cells, amplification status of the proto-
oncogene MYCN, the stage of disease, and age of the patient at presentation are 
important variables for determining the treatment and outcomes of this aggressive disease 
[1]. Despite intensive research therapeutic options for these patients, outcomes of 
children with aggressive variants of neuroblastoma continues to remains poor. 
 The treatment of neuroblastoma typically involves surgical resection and multi-
agent chemotherapy. The toxicity of chemotherapy required often limits therapy  in this 
young and fragile population. Children who receive chemotherapy at such of a young age 
are susceptible to the life long effects of the morbidities associated with these drugs 
including hepatotoxicity, nephrotoxicity  or cardiotoxicity  [5]. Further, children are at 
increased risk for developing long term side effects of these agents, such as the 
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development of myelodysplastic syndromes [5]. Any novel agent that  can effectively  treat 
this disease or serve as an adjunct to reduce the toxicities associated with current 
therapeutic options, offers the potential to limit or eliminate these devastating systemic 
toxicities and improve therapeutic outcomes in children with neuroblastoma. 
 Given the anti-cancer properties that RC has displayed in a variety of cancers 
[6-10], such as breast cancer [7-8], glioblastoma [9] and melanoma [10], this work sought 
to evaluate the effects that RC extract has both in vitro and in vivo as a novel method for 
the treatment of neuroblastoma.
 
5.2 Materials and Methods
5.2.1 RC Preparation
 RC root extract was obtained in powdered form from Barrington Chemical 
Corporation (Harrison, NY). For cell culture and oral administration experiments, RC 
powder was dissolved in a 10% ethanol solution in distilled water and was filter 
sterilized.
5.2.2 Cell Culture
 Two human neuroblastoma cell lines were evaluated for this work which were 
graciously provided by Dr. Andrew Davidoff’s labs of St. Jude’s Hospital for Children. 
The first cell line, NB-1691, is a MYCN amplified neuroblastoma line derived from a 
recurrent retroperitoneal tumor in a 1.9 year old male [11]. The second line evaluated is 
SK-N-AS, which are non-MYCN amplified cells obtained from the bone marrow of an 
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eight year old female with recurrent neuroblastoma [11]. Cells were cultured in either 
Roswell Park Memorial Institute (RPMI)-1640 medium containing 2mM of glutamine 
(Thermo Fisher, Grand Island, NY) or Dulbecco’s Modified Eagle’s Medium (DMEM, 
Thermo Fisher, Grand Island, NY). All media was supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco®, Grand Island, 
NY) and all cells were cultured at 37°C under 5% CO2.
5.2.3 Evaluation of Viability with Trypan Blue Exclusion. 
 Cell viability  was determined by  trypan blue exclusion performed on a Beckman 
Coulter Vi-Cell Cell Viability Counter (Beckman Coulter, Brea, Ca).
5.2.4 MTS Proliferation Assay 
 A CellTiter96® Aqueous One Solution MTS (Promega, Madison, WI) assay was 
performed according to the manufacturer’s directions in order to test for cell growth and 
proliferation. A total of 1X104 cells were seeded on a 96-well microtiter plate and treated 
with 0-200 µg/mL RC or ethanol vehicle control. After incubation for up to 96 hours, 
media was removed and replaced with 100µL of 1X PBS mixed with 20 µL of MTS 
reagent per well. The plate was then incubated at  37°C until color development occurred 
(between 1-4 hours). The absorbance of each well was evaluated at a wavelength of 490 
nm using an Enspire® multimode automated plate reader (Perkin Elmer, Waltham, MA).
5.2.5 Clonogenecity assay. 
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 A total of 300 NB-1691 cells were seeded onto 60-mm tissue culture dishes in 
which three plates were evaluated per treatment group. After allowing the cells to adhere 
for 24 hours, plates were then treated with 50 µg/mL RC or vehicle control. Plates were 
also additionally treated with +/- exposure to 5 Gy radiation one hour following RC 
treatment. The media was replaced with the appropriate treatment every 3-4 days. Once 
colonies were grown and established (approximately two weeks), cells were then fixed in 
methanol and stained with 2% crystal violet  in a 50% methanol solution. Colonies were 
defined as a cluster of five or more cells. The number of colonies were quantified visually 
and compared between treatment groups. The experiment was performed in triplicate.
5.2.6 Scratch Wound Migration Assay
 NB-1691 and SK-N-AS cells were plated on 30-mm dishes and allowed to reach 
100% confluency. Following this, a scratch was made down the center of each culture 
dish using a pipette tip. Plates were then treated with 100 µg/mL RC or ethanol vehicle 
control. Cell growth was monitored over 72 hours. Images of the plates were captured 
daily with Nikon Eclipse TE2000-U using Metaview™ software (Universal Imaging 
Corporation). 
5.2.7 Transwell Migration Assay
 NB-1691 cells were pretreated with 100 µg/mL RC or vehicle control (three wells 
per treatment group). After 24 hours, 1X105 cells were seeded onto a BD BioCoat™ 
migration chamber (8 µm pore) plate (Corning, Tewksbury, MA) and treated with serum-
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free RPMI. Migration chambers were placed in a 24-well plate so that they hovered 
above RPMI containing 10% FBS in order to create a gradient for cell migration. After 24 
hours of incubation, migration chamber membranes were fixed for 10 minutes with 10% 
formalin, stained with 2% crystal violet for 20 minutes, and rinsed 3 times with distilled 
H2O. Non-migrating cells were removed from the upper surface of the membrane with a 
cotton-tipped swab moistened with 1X PBS. The membrane was then mounted on a 
microscope slide with Cytoseal™ XYL mounting medium (Richard-Allan Scientific™) 
in order to evaluate the under surface of the membrane for migrated cells. Images were 
captured with an Olympus BX41 light microscope using SPOTSOFTWARE (Diagnostic 
Instruments, Inc., Sterling Heights, MI). The total number of migrating cells was 
quantified in representative images per each membrane sample obtained 10X 
magnification. 
5.2.9 RNA isolation and quantitative RT-PCR
 NB-1691 cells were treated with 10% ethanol vehicle control or 100µg/ml RC for 
24 hours. RNA was extracted from cells using Trizol (Invitrogen, Carlsbad, CA) per 
protocol utilizing acid-phenol extraction method. Following RNA extraction, up  to 10µg 
of RNA samples were then treated with DNAse (Thermo Fisher, Grand Island, NY) in 
order improve purity  of samples. RNA levels were quantified utilizing Nanodrop 
(Thermo Scientific, Wilmington, DE). 
 Relative levels of mRNA were determined by  quantitative real-time polymerase 
chain reaction (qRT-PCR) using the Strategene Mx3005P real time PCR system (Agilent 
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Technologies, La Jolla, CA). All values were normalized to the amplification of GAPDH. 
The PCR primer sequences evaluated are listed in Table 5.1. The assays were performed 
using the one-step 2X Brilliant SYBR Green qRT-PCR Master Mix Kit (Agilent 
Technologies, Santa Clara, CA) containing both 200nM  of forward primer and reverse 
primer as well as 50ng total mRNA. The conditions for target mRNA amplification were 
performed as follows: one cycle of 50°C for 30 minute; one cycle of 95°C for 10 
minutes; 35 cycles each 95°C for 30 seconds, 55°C for one minute, and 72°C for 30 
seconds.
5.2.10 Hypoxia Inducible Factor Transfection and Luciferase Assay
 NB-1691 cells were plated in a 24 well plate at 8x104cells/well and were 
transfected the following day with a reporter construct containing an inducible hypoxia 
inducible factor (HIF) promoter (Qiagen, Valencia, CA) as well as non-inducible reporter 
construct (negative control) and a constitutively  active reporter construct (positive 
control). Vectors were transfected using Lipofectamine® 2000 (Invitrogen, Carlsbad, 
CA) as per manufacturer instructions.  After 24 hours of transfection, the cells were then 
treated with either ethanol vehicle control or 100µg/ml RC for 24 hours. Cells were then 
washed with 1X PBS and lysed using 1X passive lysis buffer (Promega). Luciferase 
activity was measured using the Dual-Luciferase® reporter assay  system  (Promega) 
according to the manufacture’s instructions. Light  output was measured with a TD-20/20 
Luminometer (Turner Designs, Sunnyvale, CA), and relative luciferase activity was 
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calculated by firefly luciferase activity/renilla luciferase activity. Luciferase activity of 
vehicle control treated cells were compared to RC treated cells.
5.2.11 Evaluation of Pyruvate Supplementation on the Effects of RC on NB-1691 
Viability
 In order to evaluate if media supplementation with pyruvate alters the outcomes 
of RC treatment on NB-1691 cells, viability and growth were evaluated with trypan blue 
exclusion, an MTS assay and a clonogenicity  assay. Prior to performance of these assays, 
NB-1691 cells were grown in media conditioned with 1mM  of pyruvate.  For MTS and 
viability assays, cells were treated in suspension with 200µg/mL RC or ethanol +/- 1mM 
pyruvate. Cells were then incubated for 24 hours and assays were performed. For 
clonogenicity assays, 300 NB-1691 cells were allowed to adhere to the plate. Cells were 
then treated to 200µg/mL RC +/- 1mM  pyruvate throughout experiment. Cells were 
allowed to grow for approximately  three weeks in which colonies were established. 
Colonies were then fixed, stained and quantified.  
5.2.12 Evaluation of Nutrient Supplementation on the Effects of RC on NB-1691 
Viability
 All experiments were performed on 1X104 NB-1691 added to DMEM media 
lacking pyruvate, glucose and glutamine. Cells were then treated with 200µg/mL RC or 
ethanol vehicle control. Media was then additionally  supplemented with either 25mM 
glucose, 2mM glutamax or 0.4mM non-essential amino acids (NeAA). Treatment was 
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added to cells in suspension and cells were then plated on a 96 well microtiter plate and 
incubated for 24 hours. MTS assay was then performed to assess for viability. 
5.2.13 Evaluation of Citric Acid Cycle Intermediates on the Effects of RC on NB-1691 
Viability. 
 All experiments were performed on 2X105 NB-1691 cells which were treated with 
200µg/mL RC or vehicle control +/- one of four citric acid cycle intermediates. Those 
evaluated included: 5mM α-ketoglutarate (αkg), 5mM malate, 5mM succinate, or 5mM 
isocitrate. Treatment was added to cells in suspension and cells were then incubated for 
24 hours. Cells were washed with PBS, treated with trypsin, and viability was then 
evaluated using trypan blue exclusion using a Vi-cell counter. 
5.2.14 Evaluation of Metabolic Inhibitors on the effects of RC on NB-1691 Viability
 NB-1691 cells were treated with one of three metabolic inhibitors including:  2-
deoxy-D-glucose (2DG) which is a glucose analog that inhibits glycolysis [12], 
dichloroacetate (DCA) which inhibits pyruvate dehydrogenase kinase (PDK) which 
drives cells to utilize mitochondrial respiration [13], or rotenone which inhibits oxidative 
phosphorylation through inhibition of complex I in the mitochondrial electron transport 
chain [14]. In order to evaluate the effects of glycolytic inhibition on RC, 1X104 
NB-1691 were treated with 200µg/mL RC or ethanol +/- 11.1mM 2DG (equimolar to 
glucose concentration in the media). Cells were treated in suspension and plated on a 96 
well microtiter plate for 24 hours, following which an MTS assay was performed to 
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assess for viability. In order to evaluate mitochondrial metabolism on the effects of RC, 
2X105 cells were treated with 200µg/mL RC or ethanol +/- 20nM DCA, treated in 
suspension. Trypan blue exclusion performed utilizing a Vicell counter was performed 24 
hours after treatment to assess for viability. Finally, in order to evaluate oxidative 
phosphorylation inhibition on the effects of RC, 2X105 cells treated with 200µg/mL RC 
or ethanol +/- 50nM rotenone, treated in suspension for 24 hours. Trypan blue exclusion 
performed utilizing a Vicell counter to assess for viability.
5.2.15 Lactate Dehydrogenase Activity Assay
 NB-1691 cells were treated in microcentrifuge tubes in which 1X106 cells were 
treated in suspension with 200µg/mL RC or ETOH for a total of two hours. Samples were 
evaluated in triplicate. After two hours, samples were prepared per Lactate 
Dehydrogenase (LDH) Activity Assay (Sigma Aldrich, St. Louis, MO) protocol. Cells 
were homogenized in LDH Activity  buffer and centrifuged at 10000 X g for 15 minutes 
at 4oC. Samples were ran on a 96 well plate along with a positive control and NADH 
standards (standard concentrations evaluated included: 0 (blank), 2.5, 5, 7.5, 10, and 
12.5nmole/well). Following homogenization, 5µL of each soluble fraction of unknown 
samples were added to 45µL of LDH assay buffer. To each sample and standard, 50µl of 
master mix containing LDH assay buffer and LDH substrate mix was added. Samples 
were allowed to develop in the dark at 37oC for 2-3 minutes and then samples were 
evaluated on an Enspire® multimode automated plate reader (Perkin Elmer, Waltham, 
MA) to determine the initial [(A450)intial] absorbance at  a wavelength of 450nm. The plate 
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was then incubated at 37oC in the dark and repeat measurements were obtained every 
5-10 minutes. The samples were allowed to continue to develop until the absorbance 
value of most active samples exceeded that of the highest  NADH standard (12.5nmole/
well). The measurement prior to this was determined the “penultimate” or final [(A450)
final] measurement. LDH Activity  was determined by subtracting the blank value from 
each standard and unknown value. The [(A450)final] was then subtracted from the [(A450)
intial] and this value was compared to the standard curve to calculate the amount of NADH 
generated by LDH over the evaluated time period. Results of samples treated with 
ethanol were compared to those treated with RC. 
5.2.16 Pyruvate Kinase Activity Assay
 NB-1691 cells were treated in microcentrifuge tubes in which 5X105 cells were 
treated in suspension with 200µg/mL RC or ETOH for a total of two hours. Samples were 
evaluated in triplicate. After two hours, samples were prepared per Pyruvate Kinase (PK) 
Activity Assay  (Sigma Aldrich, St. Louis, MO) protocol. Cells were homogenized in PK 
assay buffer and centrifuged at 15,000 X g for 10 minutes. Samples were ran on a 96 well 
plate along with pyruvate standards (standard concentrations evaluated included: 0 
(blank), 2, 4, 6, 8, and 10nmole/µL). Following homogenization, 5µL of each soluble 
fraction of unknown samples were added to 40µL of PK assay  buffer. To each sample and 
standard, 50µl of master mix containing PK assay buffer, PK substrate mix, PK enzyme 
mix and fluorescent peroxidase substrate mix was added. Samples were allowed to 
develop for 2-3 minutes and then samples were evaluated on an Enspire® multimode 
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automated plate reader (Perkin Elmer, Waltham, MA) to determine the initial [(A570)intial] 
absorbance at a wavelength of 570nm. The plate was then incubated at room temperature 
in the dark and repeat measurements were obtained every 5-10 minutes. The samples 
were allowed to continue to develop  until the absorbance value of most active samples 
exceeded that of the highest pyruvate standard (10nmole/µL). The measurement prior to 
this was determined the “penultimate” or final [(A570)final] measurement. PK Activity was 
determined by subtracting the blank value from each standard and unknown value. The 
[(A570)final] was then subtracted from the [(A570)intial] and this value was compared to the 
standard curve to calculate the amount of pyruvate generated by PK over the evaluated 
time period. Results of samples treated with ethanol were compared to those treated with 
RC.
5.2.17 Nicotinamine Adenine Dinucleotide Quantification Assay
 NB-1691 cells were treated in microcentrifuge tubes in which 8X105 cells were 
treated in suspension with 200µg/mL RC or ETOH +/-1mM pyruvate for a total of two 
hours. Samples were evaluated in triplicate. After two hours, samples were prepared per 
Nicotinamine adenine dinucleotide (NAD+) Quantification protocol (Sigma Aldrich, St. 
Louis, MO). Cells were pelleted and then homogenized in 400µL of NADH/NAD 
extraction buffer. Samples were vortexed and then centrifuged at 13000 X g for 10 
minutes. Samples were run on a 96 well plate along with NADH standards (standard 
concentrations evaluated included: 0 (blank), 2, 4, 6, 8, and 10pmole/well). Following 
homogenization, samples were then filtered through a 10kDa microcentrifuge cut-off spin 
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filter (Thermo Scientific, Grand Island, NY). Then 50µL of each sample was plated on 96 
well plate and then 100µl of master mix containing NAD+ cycling buffer and NAD+ 
cycling enzyme mix was added. Samples were allowed to develop for 5 minutes and then 
10µL of NADH developer was added to each well to convert NAD to NADH. Samples 
were allowed to develop at  room temperature from 1-4 hours in which measurements 
were obtained on an Enspire® multimode automated plate reader (Perkin Elmer, 
Waltham, MA) to determine the absorbance at a wavelength of 450nm (A450) to assess for 
a total level of NADH and NAD+ together. The blank value was subtracted from each 
standard and unknown value and this value was compared to the standard curve to 
calculate the amount of NAD (NAD+ plus NADH) generated. This was then was 
compared between samples treated with ethanol and RC.
5.2.18 Evaluation of RC treatment of Disseminated Neuroblastoma In Vivo
 Twenty 6-week-old non-obese diabetic severe combined immunodeficient (NOD 
SCID) mice were pretreated for three days with RC (100 mg/kg) or ethanol vehicle 
supplemented into drinking water. A total of 1X106 NB-1691 cells were injected via 
lateral tail vein to model a disseminated disease state. Mice were evaluated daily, and 
water was replaced with appropriate treatment every 48 hours. All mice were euthanized 
38 days following tumor injection as mice began to exhibit decreasing weight. At the 
time of euthanasia, the lungs were injected with india ink and then preserved in Fekete’s 
solution. All remaining organs were preserved in 10% formalin or flash frozen in liquid 
nitrogen. Formalin-fixed paraffin-embedded livers and kidneys were further analyzed 
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histologically by H&E staining. Representative images of H&E-stained liver and kidney 
sections were taken using an Olympus BX41 light microscope using SPOTSOFTWARE 
and metastatic foci from 10X images were quantified. (Diagnostic Instruments, Inc.).
5.2.19 Statistical analysis
 All results were analyzed using either a two-tailed student’s t-test with one-way 
analysis of variance (ANOVA) or a two-ANOVA. Statistical outliers were identified 
utilizing a Grubb’s test. All graphs were made and statistical analysis was performed 
using GraphPad Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).
5.3 Results
5.3.1 In Vitro effects of RC on Neuroblastoma 
 Both cell lines were treated with 200µg/mL RC or ethanol vehicle control for 24 
hours. Upon microscopic analysis, RC treated cells in both lines were noted to have a 
significant proportion of dead or abnormal appearing cells. Morphological changes of RC 
treatment consisted of more rounded appearing cells, which were less adherent (Fig 5.1). 
Further, cells treated with RC were associated with the development of cytoplasmic 
vacuoles within several hours of treatment.
5.3.2 Cytotoxic Effects on RC on Neuroblastoma In Vitro
 In order to quantify the cytotoxic effects of RC, both cell lines were treated with 
graduated doses of RC raging from 50µg/ml to 200µg/mL over 72 hours. Strikingly, the 
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viability of NB-1691 was reduced by more then 50% upon RC treatment. SK-N-AS cells, 
in contrast, exhibited an approximate 40% decrease in viability  upon RC treatment (Fig 
5.2A, B). The cytotoxic effects were noted to be greater upon application of RC treatment 
while cells were in suspension compared to RC treatment following adherence to the 
culture plate, especially in the NB-1691 cells. An MTS calorimetric proliferation assay 
performed on both cell lines following treatment with graduated doses of RC revealed an 
approximate 20-25% reduction in proliferation compared to vehicle control upon RC 
treatment (Fig 5.2C, D).
5.3.3 RC effects on Neuroblastoma Migration and Proliferation
 The growth and proliferation of neuroblastoma cells was also markedly  affected 
by RC therapy.  A scratch wound assay  performed in both cell lines revealed a reduction 
in cell migration and wound healing upon RC treatment compared to ethanol vehicle 
control (Fig 5.3A). Additionally, a clonogenic assay of NB-1691 cells exposed to 
continuous 50µg/mL RC +/- 5gy  radiation treatment resulted in a significant reduction in 
the number of established colonies (p<0.0001). Strikingly, upon RC treatment, no 
colonies were observed, regardless of radiation exposure (Fig 5.3B). However, no 
difference in cellular migration, assessed utilizing Transwell migration inserts, was 
observed upon RC treatment on NB-1691 cells in vitro compared to vehicle control.
5.3.4 Evaluation of the Cytotoxic Effects of RC Compared to Dox
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 The cytotoxic effects of RC were compared to that of Dox, a common drug 
utilized in multi-agent treatment for high risk neuroblastoma. The cytotoxic effects of RC 
treatment was observed to be much greater than that  observed with Dox treatment in 
NB-1691 cells, especially upon RC treatment with cells in suspension. In contrast, SK-N-
AS cells were more susceptible to Dox treatment compared to RC treatment (Fig 5.4A, 
B).
5.3.5 RC Effects on Gene Expression Regulating Cellular Differentiation
 Inhibitor of DNA (Id) genes are known to play a role in cellular differentiation 
[7,9]. Reduction in the expression of ID 1, 2 and 3 was observed upon RC treatment. ID1 
and ID3 expression was significantly reduced (p<0.05) upon treatment with RC 
compared to ethanol vehicle control (Fig 5.5A).
5.3.6 RC Effects on HIF and HIF Related Gene Expression 
 In order to evaluate potential genes related to the Warburg Effect including those 
involved with nutrient uptake and cellular metabolism, qRT-PCR was performed 
evaluating the mRNA expression of HIF-1α subunit and several HIF-1 downstream 
targets including genes involved in glycolysis (HK2, PKM2), cellular transport (MCT1, 
SLC7A11, GLUT1) and angiogenesis (VEGFa, VEGFa165). This revealed a significant 
up-regulation of HIF-1α expression upon RC treatment (p<0.05). Additional up-
regulation of PKM2, VEGF and MCT1 was also observed (Fig 5.5B). Given the 
increased expression of HIF-1α, further confirmation of alterations in HIF-1 activity  was 
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performed. NB-1691 cells transfected with a HIF-luciferase reporter element exhibited a 
significant up-regulation in HIF promoter activity upon RC treatment (p=0.0094) 
compared to vehicle control, which corroborated with qRT-PCR findings (Fig 5.5C).
5.3.7 Pyruvate Rescues Cells from Cytotoxic Effects of RC
 Upon the supplementation of media with pyruvate, the viability of NB-1691 was 
rescued from the cytotoxic effects of RC. This was confirmed utilizing an MTS assay, 
trypan blue exclusion and a clonogenicity assay. Upon viability evaluation using trypan 
blue exclusion, RC resulted in a 69% reduction in viability without pyruvate, while the 
addition of pyruvate with RC resulted in only 16.6% reduction in viability, compared to 
vehicle control. While there was still a significant reduction in viability of pyruvate with 
RC compared to vehicle control (p=0.0361), an improvement in viability upon pyruvate 
with RC compared to treatment  of RC without pyruvate was also significant  (p<0.001, 
Fig 5.6B).
 MTS assay  further supported these results as RC treatment alone resulted in 
approximate 60% reduction in absorbance compared to control while the addition of RC 
with pyruvate resulted in a 40% reduction in absorbance. Ethanol treatment resulted in a 
signficant reduction in absorbance, regardless of pyruvate supplementation (p<0.01), 
however the addition of pyruvate to RC resulted in a significant improvement in 
absorbance compared to RC alone (p<0.01, Fig 5.6A). 
 Finally, a clonogenicity assay performed evaluating colony growth and formation 
following treatment with RC supplemented with pyruvate. Treatment with vehicle 
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control, regardless of the addition of pyruvate, resulted in the development of 70-125 
colonies per plate. In contrast, treatment with RC alone resulted in no colony formation, 
while pyruvate addition lead to a significant increase in the number of colonies observed 
per plate (an average of 43 colonies per plate, p<0.01, Fig 5.6C). 
5.3.8 Evaluation of Nutrient and Metabolic Intermediate Supplementation on the Effects 
of RC Treatment. 
 An MTS assay was performed on NB-1691 evaluating the effects of glucose, 
NeAA and glutamax supplementation. No significant difference upon the addition of 
glucose (Fig 5.7A), NeAA (Fig 5.7B) or glutamax (Fig 5.7C) was observed upon RC 
treatment alone compared to RC treatment supplementation with any of these nutrients. 
 The supplementation of RC treatment with citric acid cycle intermediates, 
including malate, isocitrate, αkg and succinate, was performed and trypan blue exclusion 
was utilized to establish the effect. Upon the addition of malate (Fig 5.8B), succinate (Fig 
5.8C) or isocitrate (Fig 5.8D) to RC treatment, no improvement in viability was observed. 
In contrast, cells treated with RC alone exhibited 36% viability compared to RC treated 
cells supplemented with αkg which displayed 94% viability. This rescue of the cytotoxic 
effects of RC upon αkg supplementation compared to RC treatment alone was significant 
(p<0.001, Fig 5.8A). 
5.3.9 Effect of Metabolic Inhibitors on RC Treatment upon NB-1691 Cells In Vitro
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 The effects of glycolysis inhibition on the effects of RC was evaluated by 
treatment with 2DG followed by an MTS assay. Upon treatment of NB-1691 cells with 
2DG, a significant reduction in the absorbance of cells treated with 2DG and ethanol 
compared to ethanol alone was observed (p<0.001). Despite this, cells treated with 2DG 
and ethanol still displayed greater absorbance than cells treated with 2DG and RC 
(p<0.001). Additionally, 2DG treatment with RC did result in a slight decrease in 
absorbance compared to RC treatment alone (p<0.01, Fig 5.9A).
 Viability was evaluated upon the inhibition of PDK in the setting of RC treatment 
utilizing DCA. DCA did not result in decreased viability  upon cells treated with ethanol 
(Fig 5.9B). Additionally, the viability of RC treatment remained unchanged upon the 
addition of DCA as well.
 Viability was also evaluated upon the inhibition of oxidative phosphorylation in 
the setting of RC treatment utilizing rotenone. Similar to DCA, rotenone did not result in 
reduced viability of NB-1691 cells treated with ethanol (Fig 5.9C). Further, rotenone 
treatment did not further reduce the viability of cells treated with RC. 
5.3.10 Evaluation of RC Effect on PK Activity
 PK activity was observed to be significantly  increased upon treatment with 
200µg/mL RC compared to ethanol treated NB-1691 cells following two hours of 
treatment (p=0.0081). Ethanol treated cells exhibited an approximate 48nM/min/mL rate 
of PK activity while RC treated cells displayed an approximate 65nM/min/mL rate of PK 
activity (Fig 5.10A). 
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5.3.11 Evaluation of RC Effect on LDH Activity
 LDH activity was observed to be significantly  reduced upon treatment with 
200µg/mL RC compared to ethanol treated NB-1691 cells following two hours of 
treatment (p=0.0196). On average ethanol treated cells exhibited 24mU/mL rate of LDH 
activity while RC treated cells had a 16mU/mL rate of LDH activity (Fig 5.10B).
5.3.12 Evaluation of RC Effects on Total Cellular NAD Levels
 A significant reduction in the total NAD (NAD++NADH) levels was observed 
upon treatment with 200µg/mL RC in NB-1691 cells following two hours of treatment 
(p<0.001, Fig 5.10C). RC treated cells had about 75% less total NAD then ethanol treated 
cells. The total amount of NAD was increased upon the addition of 1mM  pyruvate to 
cells resulting in no significant difference between ethanol and RC treatment groups in 
the presence of pyruvate. 
5.3.13 In Vivo Evaluation of RC Effects on Disseminated Neuroblastoma
 The effect of RC on prevention of metastatic when decreasing weights were 
observed in mice (Fig 5.11A). At the time of euthanasia, there was no difference in the 
weight of mice between treatment groups (Fig 5.11B). Upon necropsy, the greatest 
burden of metastatic foci was observed in the liver and kidneys in both treatment groups 
and there was no gross difference observed in metastatic establishments of tumor 
between treatment groups.  There were no differences in the weights of organs, including 
88
liver, kidney, spleen, heart and lungs, between treatment groups (Fig 5.12A). The liver 
and kidneys were further evaluated histologically. The average number of metastatic foci 
observed in representative 10X images of liver and kidneys for all animals again revealed 
no difference in tumor burden between mice treated with ethanol and RC (Fig 5.12A, B). 
5.4 Discussion
 Neuroblastoma remains one of the deadliest childhood cancers. Outcomes of 
aggressive variants of this disease result in high mortality  rates and investigation into 
novel treatment methods may lead to improved outcomes for this patient population in 
the future. Through this work, we identified that RC results in the striking development 
of neuroblastoma cytoxicity in vitro. Further, RC treatment results in reduced growth and 
proliferation of these cells. These cytotoxic effects are likely secondary to metabolic 
derangements afforded by  treatment with this extract resulting in cell death. While there 
was no improvement in outcomes observed upon RC treatment in a disseminated model 
of neuroblastoma, given the in vitro findings observed, RC still offers therapeutic 
potential for the treatment of neuroblastoma. 
 Upon investigation of RC treatment on neuroblastoma cells in vitro, two cell 
culture lines were evaluated, one which was MYCN amplified (NB-1691) and another 
without MYCN amplification (SK-N-AS). MYCN is a critical oncogene for determining 
the aggressiveness of a patient’s tumor, as amplification of MYCN is associated with 
more advanced and aggressive disease as well as poorer outcomes [1-4]. To this end, 
while RC treatment resulted in reduced viability in both cell lines, surprisingly the effects 
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of RC were enhanced upon treatment on NB-1691 cells. These effects were even more 
pronounced upon treatment of cells prior to adherence to the culture dish. In contrast, SK-
N-AS cells were more susceptible to the effects of Dox, a common chemotherapeutic 
agent utilized for the treatment of neuroblastoma in the clinical setting [1,5] while 
NB-1691 were much less sensitive to Dox. Given these findings, our further efforts into 
the investigation of the effects of RC on neuroblastoma were focused on the NB-1691 
cell line given that these cells remained more susceptible to RC. 
 In addition to the cytotoxic effects that RC conferred upon neuroblastoma cells, 
RC also resulted in reduced growth as well as alterations in genetic expression. RC 
resulted in a significant reduction in the expression of Id genes. Numerous types of 
cancers have revealed alteration in Id gene expression upon RC treatment [7,9]. As Id 
genes are associated with cellular differentiation, RC treatment may also result in a 
reduction in the patterns of cell growth and differentiation resulting in a less aggressive 
tumor phenotype. 
 RC treatment resulted in a rapid cytotoxicity, in which reduced growth and 
increased cell death were observed within 24 hours of treatment. Further, alterations in 
genetic expression and enzymatic activity  were observed in as little as two hours 
following treatment. Upon RC treatment of NB-1691 in culture, cells began to develop 
cytoplasmic vacuoles, suggestive of cellular damage and/or autophagy, within several 
hours. We hypothesized that the causes for these effects could be attributable to nutrient 
deficiencies, oxidative damage or derangements to cellular metabolism. 
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 In order to evaluate the means to which RC exerts it’s cytotoxic effects on 
NB-1691 cells, a variety of metabolic nutrients and intermediates were provided upon RC 
treatment. Interestingly, pyruvate as well as αkg resulted in significant rescue in cell 
viability in the setting of RC treatment. The addition of glucose, NeAA or glutamax, as 
well as other citric acid cycle intermediates, failed result in any appreciable improvement 
in cell viability  upon RC treatment. This reveals that the effects of RC are, at least 
partially, reversible and are dependent upon the availability  of key nutrients to prevent the 
development of cell death. 
 The Warburg effect states that the growth of rapidly proliferating cells, such as 
cancers, are more dependent on glycolysis, even in aerobic conditions. This is achieved 
through enhanced cellular glucose uptake as well as promotion of glycolysis over 
mitochondrial dependent cellular respiration [15-18]. HIF is believed to play a key role in 
the Warburg Effect as a “switch” in cancer development as it promotes glycolysis as 
favored cellular metabolism [19, 20]. While we observed that  HIF expression and it’s 
transcriptional activity are increased upon RC treatment, these results are likely 
secondary to the cellular stress imposed by RC treatment.
 HIF is a key regulator of cellular metabolism and in cancer cells enhances 
glycolytic activity and reduces mitochondrial respiration. To this end, elevations in HIF 
activity typically  result in enhanced the activity of LDH [21, 22], furthering anaerobic 
metabolism and restoring cellular levels of NAD for continued use in glycolysis [23]. 
Despite elevated HIF expression observed upon RC treatment, the activity of LDH was 
noted to be decreased and PK activity was observed to be increased. Additionally, the 
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total cellular levels of NAD were significantly reduced upon RC treatment compared to 
vehicle treated cells. Therefore RC treatment potentially prevents optimal functioning of 
cellular metabolism that maintains the Warburg Effect as changes in enzymatic activity 
observed upon RC treatment drives the cells away from glycolysis. Further, given 
reduced cellular NAD levels observed upon RC treatment, effective cellular metabolism 
can not be continued efficiently to maintain cellular growth and viability. Future work 
will focus on further defining the mechanism to which RC affects the cellular metabolism 
of neuroblastoma and it’s association with cellular viability. 
 Given the observation of the effects that RC exerts on NB-1691 cells, further 
investigation into the in vivo effects of RC on neuroblastoma was performed. To this end, 
a disseminated model of neuroblastoma was investigated as RC has previously  been 
shown to prevent the establishment of both primary tumors and metastastic lesions [6,8]. 
Mice were provided RC enterally and then NB-1691 were injected via the lateral tail vein 
to create a disseminated disease state. Despite positive outcomes upon RC treatment 
observed upon investigations of other tumors, such as melanoma, we did not observe any 
difference in the establishment of metastatic neuroblastoma upon RC treatment. Several 
reasons may have contributed to these results. First, as NB-1691 cells are derived from 
human neuroblastoma, immunodeficient NOD SCID mice were utilized. RC is known to 
be immuno-modulatory and through the use of NOD SCID mice, the benefits of the 
immunologic changes resulting from RC treatment may have been lost. Secondly, as 
neuroblastoma cells can be rescued from the cytotoxic effects of RC upon 
supplementation with nutrients such as pyruvate, the availability of these nutrients 
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systemically may prevent RC from affecting circulating neuroblastoma cells.  Alternative 
evaluation of orthotopic neuroblastoma or evaluation of alternative neuroblastoma cell 
lines in an immunocompetent mouse may result  in improved outcomes upon RC 
treatment. 
5.5 Conclusion
 Through this work, dramatic cytotoxic and anti-proliferative effects following RC 
treatment on neuroblastoma in vitro were observed. Strikingly these effects are more 
pronounced in NB-1691 cells, despite it’s MYCN amplified status. The in vitro effects of 
RC appear to result from alterations in the metabolic functioning of the cell resulting in 
rapid cytotoxicity. These findings are promising as a novel adjuvant therapyfor 
neuroblastoma. Despite our in vitro findings, RC treatment failed to result in an improved 
outcome upon treatment in a disseminated model of neuroblastoma in vivo. However, RC 
treatment may still prove to be efficacious for the treatment of neuroblastoma as it may 
improve outcomes for the treatment of solid tumors or as an adjunct therapy to other 
chemotherapeutic agents. Further work is required to assess the therapeutic benefits of 
Rhodiola plant extracts for the treatment of neuroblastoma.
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5.6 Figures
Figure 5.1. Morphological Effects of RC Treatment on Neuroblastoma Cells In Vitro. Phase 
contrast  images of live neuroblastoma cells, both SK-N-AS (A, B) and NB-1691 (C, D) cell lines, 
were performed following 24 hours of ethanol vehicle (A, C) and RC treatment (B, D).
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Figure 5.2. Cytotoxic Effects of RC on Neuroblastoma In Vitro. A) 72 hour viability evaluated 
with trypan blue exclusion on NB-1691 (black) and SK-N-AS (red) cells following treatment 
with RC, dose including 0, 50, 100, 200µg/mL upon treatment  in suspension. B) 72 hour viability 
evaluated with trypan blue exclusion on NB-1691 and SK-N-AS cells treated with 0, 50, 100, 
200µg/mL RC following plate adherence. C) MTS assay performed on SK-N-AS cells treated 
with 0, 10, 50, 100, and 200µg/mL RC in suspension. Results presented as absorbance relative to 
vehicle control treated cells following 24 hours of treatment. D) MTS assay performed on 
NB-1691 cells treated with 0, 10, 50, 100, and 200µg/mL RC in suspension. Results presented as 
absorbance relative to vehicle control treated cells following 24 hours of treatment. Error Bars 
indicate +/- standard error of the mean, *=p<0.05, **=p<0.01
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Figure 5.3. Evaluation of RC’s Effect on Migration and Growth on Neuroblastoma In  Vitro 
A) Scratch wound was created in confluent monolayer of SK-N-AS and NB-1691 then treated 
with either ethanol or 200µg/mL RC. Representative images following 4 and 72 hours of 
treatment with either vehicle control or RC are shown. Red and blue lines outline borders of 
growth within scratch wound. B) Clonogenicity evaluation of NB-1691 treated with 50µg/mL RC 
or ethanol vehicle control +/- 5Gy radiation. RC treatment was applied continuously. C) The 
average number of cells treated with either ethanol or 100µg/mL RC that migrated through 
transwell migration wells quantified in each representative 10X field. Error Bars indicate +/- 
standard error of the mean, *=p<0.05, **=p<0.01, ****=p<0.0001.
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Figure 5.4. Evaluation of RC vs Dox treatment on  Neuroblastoma In Vitro. 72 hour viability 
evaluated using trypan blue exclusion of SK-N-AS (A) and NB-1691 (B) cells performed 
following treatment with 200µg/mL RC both before and after adherence to the plate. Results were 
compared to 10µg/mL Dox treatment. Results presented as viability relative to ethanol control 
treated cells.  Error Bars indicate +/- standard error of the mean, *=p<0.01, **=p<0.001.
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Figure 5.5. Effects on Gene Expression upon RC treatment in NB-1691 In Vitro. A) 
Quantitative RT-PCR was performed from RNA extracted from NB-1691 cells treated with 
100µg/mL RC or ethanol vehicle control for 24 hours. Changes in mRNA levels normalized to 
GAPDH expression of ID 1, ID 2, and ID 3 gene expression. B) Changes in mRNA levels 
normalized to GAPDH expression of HIF-1 targets including HIF1-α, HK2, PKM2, VEGF, 
VEGFa165, MCT1, SLC7A11 and GLUT1.  C) NB1691 cells transfected with luciferase reporter 
HIF-1 promoter and treated with 100µg/mL RC or ethanol vehicle for 48 hours. Luciferase 
activity was evaluated and relative luciferase activity is reported.  Error Bars indicate +/- standard 
error of the mean, *=p<0.05 and **=p<0.01.
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Figure 5.6 Evaluation of the Effects of Pyruvate  Upon RC  Treatment on Neuroblastoma. A) 
MTS assay performed on NB-1691 cells treated with 200µg/mL RC or ETOH +/- Pyruvate 
(1mM) following 24 hours of treatment. B) Assessment of viability utilizing trypan blue 
exclusion on NB-1691 cells treated with 200µg/mL RC or ETOH +/- Pyruvate. C) Clonogenicity 
evaluation of NB-1691 treated with 50µg/mL RC or ethanol vehicle control +/- 1mM Pyruvate. 
RC treatment was applied continuously and plates were evaluated for the development of colony 
formation over three weeks. Following this, cells were fixed and stained with crystal violet and 
total colonies formed were quantified. Error Bars indicate +/- standard error of the mean, 
*=p<0.05.
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Figure 5.7. Evaluation of Nutrient Supplementation  on RC  Effects on Neuroblastoma 
Viability In Vitro. All experiments were performed on 1X104 NB-1691 cells treated with RC or 
ethanol in suspension +/- listed nutrient in DMEM lacking pyruvate, glucose and glutamine. Cells 
were incubated for 24 hours and then an MTS assay was performed to assess for cell viability. A) 
Evaluation of the effects of glucose (25mM) on RC treatment. B) Evaluation of the effects of 
non-essential amino acids (0.4mM) on RC treatment. C) Evaluation of the effects of glutamax 
(2mM) on RC treatment. Error Bars indicate +/- standard error of the mean, *=p<0.05.  
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Figure 5.8. Evaluation of Citric Acid Cycle Intermediate Supplementation on RC Effects on 
Neuroblastoma Viability In Vitro.  All experiments were performed on 2X105 NB-1691 cells 
pre-conditioned in pyruvate (1mM) containing medium. Cells were treated with 200µg/mL RC or 
vehicle control +/- 5mM α-ketoglutarate (A), +/- 5mM malate (B), +/- 5mM succinate (C), +/- 
5mM isocitrate (D) in suspension and incubated for 24 hours. Viability was evaluated using 
trypan blue exclusion using a Vi-cell counter. Error Bars indicate +/- standard error of the mean, 
*=p<0.05.
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Figure 5.9. Effect of Metabolic Inhibitors  on RC Treatment upon NB-1691 Cells In Vitro. A) 
1X104 cells treated with 200µg/mL RC or ethanol +/- 11.1mM 2-deoxy-D-glucose (2DG), treated 
for 24 hours and MTS assay was performed to assess for viability. B) 2X105 cells treated with 
200µg/mL RC or ethanol +/- 20nM dichloroacetate (DCA), treated in suspension for 24 hours. 
Trypan blue exclusion performed utilizing a Vicell counter was utilized to assess for viability. C) 
2X105 cells treated with 200µg/mL RC or ethanol +/- 50nM Rotanone, treated in suspension for 
24 hours. Trypan blue exclusion performed utilizing a Vicell counter was utilized to assess for 
viability.
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Figure 5.10 RC Effects  on Metabolic Enzyme Activity and Metabolic Intermediate  Levels. 
A) Pyruvate Kinase Activity levels evaluated upon NB-1691 treated for two hours with either RC 
200µg/mL or ETOH. Results show both PK activity (nM/min/mL) for each sample as well as PK 
activity over time. B)Lactate Dehydrogenase Activity levels evaluated upon NB-1691 treated for 
two hours with either RC 200µg/mL or ETOH. Results shown include LDH activity (mU/mL) for 
each sample as well as LDH activity over time. C) NAD Quantification Assay performed in 
NB-1691 cells treated with 200µg/mL RC or ETOH +/-1mM pyruvate for two hours in which 
total NAD+NADH levels were quantified. Error bars represent +/- standard error of the mean, 
*=p<0.05.
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Figure  5.11. Evaluation of the  In Vivo Efficacy of RC Treatment of Disseminated 
Neuroblastoma. A) Graphic representation of the weight  changes of mice treated with 100mg/kg 
RC or ETOH with disseminated NB-1691 over time. Arrows represent dates of RC treatment 
initiation (RC) and tail vein injection (TVI). B)Weight  change at time of euthanasia of mice 
treated with 100mg/kg RC or ETOH. Error bars represent +/- standard error of the mean.
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Figure 5.12. Outcomes of RC treatment in a disseminated in vivo  neuroblastoma model. A) 
Proportional total weights of organs collected at  time of euthanasia including from mice treated 
with either 100mg/kg RC or ETOH. Organs represented include liver, kidney, spleen, lung and 
heart. B) Average number of metastatic lesions established in kidneys present  within each 10X 
field. Representative 10X images of kidney samples from each treatment  group shown, arrows 
represent metastatic lesions. C) Average number of metastatic lesions established in livers present 
within each 10X field. Representative 10X images of liver samples from each treatment group 
shown, arrows represent metastatic lesions. Error bars represent +/- standard error of the mean
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5.7 Tables
Table 5.1 - Primers Utilized in qRT-PCR. List of primers utilized for qRT-PCR to evaluate the 
effects of RC treatment of NB-1691 cells on genetic expression. 
Gene Forward Sequence Reverse Sequence
GAPDH 5‘-TGCACCACCAACTGCTTAGC-3’ 5‘-GGCATGGACTGTGGTCATGAG-3’
ID1 5‘-CCAGAACCGCAAGGTGAG-3’ 5‘-GGTCCCTGATGTAGTCGATGA-3’
ID2 5’-GACAGAACCAGGCGTCCA-3’ 5’-AGCTCAGAAGGGAATTCAGATG-3’ 
ID3 5’-CATCTCCAACGACAAAAGGAG-3’ 5’-CTTCCGGCAGGAGGGTT-3’ 
HIF1 5’-CTCACCAGACAGAGCAGGAA-3’ 5’-TGCGAAGCTATTGTCTTTGG-3’
HK2 5’-TCGAGTACATGGGCATGAAGG-3’ 5’-ACTTGAGGAGGATGCTCTCGT-3’
PKM2 5’-CCACTTGCAATTATTTGAGGAA-3’ 5’-GTGAGCAGACCTGCCAGACT-3’
MCT1 5’-GTCATTGGAGGTCTTGGGCT-3’ 5’-GCCAATGGTCGCCTCTTGTA-3’
SLC7A11 5’-GGCAACCGCGTAATACTTG-3’ 5’-TTGCAAGCTCACAGCAATTC-3’
GLUT1 5’-GGTTGTGCCATACTCATGACC-3’ 5‘CAGATAGGACATCCAGGGTAGC-3’
VEGFa 5’-CCACGTCAGAGAGCAACATC-3’ 5’-TCTCCTATGTGCTGGCTTTG-3’
VEGFa165 5’-ATCTTCAAGCCATCCTGTGTGC-3’ 5’-CAAGGCCCACAGGGATTTTC-3’
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CHAPTER 6
CONCLUSION
6.1 General Discussion 
 Cancer remains one of the leading cause of death in the United States today. 
While significant improvements to commonly used treatment agents as well as creation 
or identification of novel therapeutic options have been made, the mortality rates of 
cancer continues to remains high. Further, it’s treatments are limited by the toxicities 
associated with the many of these chemotherapeutic agents. Development and evaluation 
of novel methods to treat various forms of cancer may lead to improved survival as well 
as reduced off target  side effects and their associated morbiditities. This work sought to 
evaluate novel treatment methods for several types of chemo-resistant cancer both in 
vitro and in vivo. 
6.2 Utilization of PolyMPC for Cancer Therapeutics
  PolyMPC produgs have previously been shown to improve survival upon the 
treatment of a murine model of breast cancer in immunocompetent mice. While these 
findings were promising, the safety  of the scaffold polyMPC polymer, as well as 
evaluation of polyMPC prodrugs (polyMPC-Dox), had yet  to be evaluated in a human 
cancer model. Through this work we observed that polyMPC polymers were extremely 
safe for systemic administration in mice. Limits to therapeutic administration of the 
polymer were secondary  to the viscosity of the polymer solution and the inability to 
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further dilute higher doses of polymer effectively. No appreciable side effects were 
observed following administration of large doses of polyMPC. Investigation of the 
therapeutic efficacy of polyMPC-Dox upon treatment of a human ovarian tumor in NOD 
SCID mice further confirmed the prior investigation of polyMPC-Dox in 
immunocompetent mice. Mice treated with polyMPC-Dox displayed increased tumor 
uptake of Dox. Additionally, treatment with polyMPC-Dox resulted in improved survival 
of mice compared to control and free Dox treated mice. In comparison to doxil, an 
alternative Dox formulation, treatment tolerance and survival was much improved in 
mice treated with polyMPC-Dox.
 Further investigation to improve targeting of polyMPC directly to tumors was 
also evaluated. Mesenchymal stem cells, which have inherent tumoritropic capabilities, 
were investigated as a vehicle to improved targeted delivery of polyMPC to tumor. We 
observed that polyMPC can be stably  loaded with polyMPC and that the in vivo 
migratory capabilities of these cells were unaltered. 
6.3 Utilization of Rhodiola Extract for the Treatment of Cancer 
 RC is an adaptogenic phytochemical that has been observed to have anti-tumor 
properties, observed both in vitro and in vivo. Given these findings, we sought to evaluate 
the effects of RC on two aggressive forms of cancer derived from the neural crest. For 
both neuroblastoma and melanoma, we observed that RC lead to reduced viability, 
growth and proliferation in vitro. Further investigation into the mechanism to which RC 
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exerts it’s cytotoxic effects upon neuroblastoma treatment revealed that RC resulted in 
changes in the metabolic activity of cells, likely resulting in cell death. 
 Upon evaluation of both cancers in a disseminated model to mimic metastatic 
disease in vivo, RC lead to reduced establishment of pulmonary melanoma lesions, 
although no difference in the establishment  of neuroblastoma lesions was observed. Upon 
investigation of the topical application of RC on subcutaneous melanoma lesions, tumors 
were observed to grow more radially and tumors displayed reduced mitotic activity. 
6.4 Conclusion
 Through this thesis, I have evaluated alternative treatment options for the several 
aggressive and chemo-resistant forms of cancer. Two broad approaches were evaluated 
for this work in which both polyMPC prodrugs and Rhodiola based plant extracts were 
utilized to treat cancer. Both polyMPC prodrugs and RC have the potential to broaden our 
arsenal of anti-cancer agents that be to be employed in humans for the treatment of 
cancer in the future. 
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